Seppo Ylä-Herttuala

Kolosowska, Natalia; Gotkiewicz, Maria; Dhungana, Hiramani; Giudice, Luca; Giugno, Rosalba; Box, Daphne; Huuskonen, Mikko T.; Korhonen, Paula; Scoyni, Flavia; Kanninen, Katja M.; Ylä-Herttuala, Seppo; Turunen, Tiia A.; Turunen, Mikko P.; Koistinaho, Jari; Malm, Tarja. 2020. Intracerebral overexpression of miR-669c is protective in mouse ischemic stroke model by targeting MyD88 and inducing alternative microglial/macrophage activation Journal of neuroinflammation 17: 194. 2020

Schenkwein, Diana; Afzal, Saira; Nousiainen, Alisa; Schmidt, Manfred; Ylä-Herttuala, Seppo. 2020. Efficient Nuclease-Directed Integration of Lentivirus Vectors into the Human Ribosomal DNA Locus Molecular therapy 28 8: 1-18. 2020

Leino, A; Westeren-Punnonen, S; Töyräs, J; Myllymaa, S; Leppänen, T; Ylä-Herttuala, S; Muraja-Murro, A; Kantanen, AM; Autere, J; Jäkälä, P; Mervaala, E; Myllymaa, K. 2020. Acute stroke and TIA patients have specific polygraphic features of obstructive sleep apnea Sleep and breathing [Epub ahead of print 14 Jan 2020]: 1-11. 2020

Yang, Ying; Liu, Yan; Li, Yiping; Chen, Zhongli; Xiong, Yixin; Zhou, Taicheng; Tao, Wenyu; Xu, Fan; Yang, Hanling; Ylä-Herttuala, Seppo; Chaurasia, Shyam S; Whaley-Connell, Adam; Yang, Ke. 2020. MicroRNA-15b Targets VEGF and Inhibits Angiogenesis in Proliferative Diabetic Retinopathy Journal of clinical endocrinology and metabolism Published: 14 August 2020: 1-37. 2020

Vuorio, Taina; Ylä-Herttuala, Seppo. 2020. Imusuonten merkitys sepelvaltimotaudissa Duodecim 136 11: 1326-1332. 2020

Valkama, Anniina J; Oruetxebarria, Igor; Lipponen, Eevi M; Leinonen, Hanna M; Käyhty, Piia; Hynynen, Heidi; Turkki, Vesa; Malinen, Joonas; Miinalainen, Tuukka; Heikura, Tommi; Parker, Nigel R; Ylä-Herttuala, Seppo; Lesch, Hanna P. 2020. Development of Large-Scale Downstream Processing for Lentiviral Vectors Molecular therapy. Methods & clinical development 17: 717-730. 2020

Taavitsainen, J; Tarvainen, S; Kuivanen, A; Mangiardi, EK; Guelcher, M; Martin, J; Mathur, A; Hytönen, JP; Ylä-Herttuala, S. 2020. Evaluation of Biodegradable Stent Graft Coatings in Pig and Rabbit Models Journal of vascular research 57: 65-75. 2020

Ståhle, Miia; Silvola, Johanna MU; Hellberg, Sanna; de Vries, Margreet; Quax, Paul HA; Kroon, Jeffrey; Rinne. Petteri; de Jong, Alwin; Liljenbäck, Heidi; Savisto, Nina; Wickman, Anna; Stroes, Erik SG; Ylä-Herttuala, Seppo; Saukko, Pekka; Abrahamsson, Tommy; Pettersson, Knut; Knuuti, Juhani; Roivainen, Anne; Saraste, Antti. 2020. Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice JACC : Basic to translational science 5 4: 360-373. 2020

Virta, Jenni; Hellberg, Sanna; Liljenbäcka, Heidi; Ståhle, Mia; Silvola, Johanna MU; Huusko, Jenni; Söderström, Mirva; Knuuti, Juhani; Nuutila, Pirjo; Ylä-Herttuala, Seppo; Gomezi, Maria F; Roivainen, Anne; Saraste, Antti. 2020. Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A 18F-fluorodeoxyglucose study of a mouse model of atherosclerosis and type 2 diabetes Atherosclerosis in press, journal pre-proof: -. 2020

Saari, H; Turunen, T; Lõhmus, A; Turunen, M; Jalasvuori, M; Butcher, SJ; Ylä-Herttuala, S; Viitala, T; Cerullo, V; Siljander, PRM; Yliperttula, M. 2020. Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery Journal of extracellular vesicles 9 1: 1747206. 2020

Olsson, Venla; Niittykoski, Minna; Stedt, Hanna; Virsunen, Heli; Ylä-Herttuala, Seppo. 2020. Pahanlaatuisen gliooman hoidon tulevaisuuden näkymiä Duodecim 136 10: 1242-1248. 2020

Nivajärvi, R; Olsson, V; Hyppönen, V; Bowen, S; Leinonen, HM; Lesch, HP; Ardenkjaer-Larsen, JH; Gröhn, OHJ; Ylä-Herttuala, S; Kettunen, MI. 2020. Detection of lentiviral suicide gene therapy in C6 rat glioma using hyperpolarised [1-13 C]pyruvate Nmr in biomedicine 33 4: e4250. 2020

Mäkinen, P; Ruotsalainen, AK; Ylä-Herttuala, S. 2020. Nucleic Acid-Based Therapies for Atherosclerosis Current atherosclerosis reports 22 2: 10. 2020

Lähteenvuo, Johanna; Hätinen, Olli-Pekka; Kuivanen, Antti; Huusko, Jenni; Paananen, Jussi; Lähteenvuo, Markku; Nurro, Jussi; Hedman, Marja; Hartikainen, Juha; Laham-Karam, Nihay; Mäkinen, Petri; Räsänen, Markus; Alitalo, Kari; Rosenzweig, Anthony; Ylä-Herttuala, Seppo. 2020. Susceptibility to Cardiac Arrhythmias and Sympathetic Nerve Growth in VEGF-B Overexpressing Myocardium Molecular therapy 28 7: 1-10. 2020

Leinonen, Hanna; Lepola, Saana; Lipponen, Eevi Maria; Heikura, Tommi; Koponen, Tiina; Parker, Nigel R; Ylä-Herttuala, Seppo; Lesch, Hanna. 2020. Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production Human gene therapy 31 5-6: 376-384. 2020

Pajula, JJ; Halonen, PJ; Hätinen, OP; Ylä-Herttuala, S; Nurro, J. 2020. Adenoviral gene transfer of Gremlin modulates VEGF-A induced angiogenesis in porcine myocardium Human gene therapy 31 3-4: 211-218. 2020

Turunen, TA; Roberts, TC; Laitinen, P; Väänänen, MA; Korhonen, P; Malm, T; Ylä-Herttuala, S; Turunen, M. 2019. Changes in nuclear and cytoplasmic microRNA distribution in response to hypoxic stress Scientific reports 9: 10332. 2019

Setaro, Francesca; Wennink, Jos W H; Mäkinen, Petri I; Holappa, Lari; Trohopoulus, Panagiotis N; Ylä-Herttuala, Seppo; van Nostrum, Cornelus F; De la Escosura, Andres; Torres, Tomás. 2019. Amphiphilic Phthalocyanines in Polymeric Micelles: A Supramolecular Approach toward Efficient Third-Generation Photosensitizers Journal of materials chemistry. b 2020; 8 2: 282-289. 2019

Sopo, M; Anttila, M; Hämäläinen, K; Kivelä, A; Ylä-Herttuala, S; Kosma, VM; Keski-Nisula, L; Sallinen, H. 2019. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer Bmc cancer 19: 584. 2019

Tirronen, Annakaisa; Hokkanen, Krista; Vuorio, Taina; Ylä-Herttuala, Seppo. 2019. Recent advances in novel therapies for lipid disorders Human molecular genetics 28 R1: R49-R54. 2019

Ylä-Herttuala, Seppo. 2019. Gene Therapy of Critical Limb Ischemia Enters Clinical Use Molecular therapy 27 12: 2053. 2019

Ylä-Herttuala, Elias; Saraste, Antti; Knuuti, Juhani; Liimatainen, Timo; Ylä-Herttuala, Seppo. 2019. Molecular Imaging to Monitor Left Ventricular Remodeling in Heart Failure Current cardiovascular imaging reports 12 4: 11. 2019

Ylä-Herttuala, Seppo. 2019. ASGCT Annual Meeting 2019 Molecular therapy 27 8: 1339. 2019

Ylä-Herttuala, Seppo. 2019. Gene and Cell Therapy: Success Stories and Future Challenges Molecular therapy 27 5: 891-892. 2019

Leinonen, HM; Lipponen, EM; Valkama, AJ; Hynynen, H; Oruetxebarria, I; Turkki, V; Olsson, V; Kurkipuro, J; Samaranayake, H; Määttä, A-M; Parker, NR; Ylä-Herttuala, S; Lesch, HP. 2019. Preclinical proof-of-concept, analytical development and commercial scale production of lentiviral vector in adherent cells Molecular therapy. Methods & clinical development 15: 63-71. 2019

Sallinen, H; Janhonen, S; Pölönen, P; Niskanen, H; Liu, OH; Kivelä, A; Hartikainen, JM; Anttila, M; Heinäniemi, M; Ylä-Herttuala, S; Kaikkonen, MU. 2019. Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma Bmc cancer 19: 1121. 2019

Plote, Devin; Choi, Woonyoung; Mokkapati, Sharada; Sundi, Debasish; Ferguson, James E, III; Duplisea, Jon; Parker, Nigel R; Ylä-Herttuala, Seppo; McConkey, David; Schluns, Kimberly S; Dinney, Colin P. 2019. Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation Oncoimmunology 8 5: e1577125. 2019

Laakkonen, Johanna P; Lähteenvuo, Johanna; Jauhiainen, Suvi; Heikura, Tommi; Ylä-Herttuala, Seppo. 2019. Beyond endothelial cells: Vascular endothelial growth factors in heart, vascular anomalies and placenta Vascular pharmacology 112: 91-101. 2019

Grönman, M; Tarkia, M; Stark, C; Vähäsilta, T; Kiviniemi, T; Lubberink, M; Halonen, P; Kuivanen, A; Saunavaara, V; Tolvanen, T; Teuho, J; Teräs, M; Savunen, T; Pietilä, M; Ylä-Herttuala, S; Roivainen, A; Knuuti, J; Saraste, A. 2019. Assessment of myocardial viability with [15O]water PET: A validation study in experimental myocardial infarction Journal of nuclear cardiology [First Online: 17 July 2019]: 1-10. 2019

Jauhiainen, Suvi; Laakkonen, Johanna P; Ketola, Kirsi; Toivanen, Pyry, I; Nieminen, Tina; Ninchoji, Takeshi; Levonen, Anna-Liisa; Kaikkonen, Minna U; Ylä-Herttuala, Seppo. 2019. Axon Guidance-Related Factor FLRT3 Regulates VEGF-Signaling and Endothelial Cell Function Frontiers in physiology 10: 224. 2019

Aavik, Einari; Babu, Mohan; Ylä-Herttuala, Seppo. 2019. DNA methylation processes in atheosclerotic plaque Atherosclerosis 281: 168-179. 2019

Asano, T; Hytönen, J; Chichareon, P; Taavitsainen, J; Kogame, N; Katagiri, Y; Miyazaki, Y; Takahashi, K; Modolo, R; Komiyama, H; Tenekecioglu, E; Sotomi, Y; Wykrzykowska, JJ; Piek, JJ; Martin, J; Baumbach, A; Mathur, A; Onuma, Y; Ylä-Herttuala, S; Serruys, PW. 2019. Serial Optical Coherence Tomography at Baseline, 7 Days, and 1, 3, 6 and 12 Months After Bioresorbable Scaffold Implantation in a Growing Porcine Model Circulation journal 83 3: 556-566. 2019

Frederickson, Robert M; Ylä-Herttuala, Seppo. 2019. Two Decades of Molecular Therapy: The Journey Continues Molecular therapy 27 1: 1-2. 2019

Banerjee, Shubhadeep; Sengupta, Jayeeta; Aljarilla, Ana; Setaro, Francesca; Mäkinen, Petri I; Wu, LinPing; Holappa, Lari; de la Escosura, Andres; Martinelli, Chiara; Trohopoulos, Panagiotis N; Ylä-Herttuala, Seppo; Urbanics, Rudolf; Szebeni, Janos; Torres, Tomas; Krol, Silke. 2019. Human serum albumin nanoparticles loaded with phthalocyanine dyes for potential use in photodynamic therapy for atherosclerotic plaques Precision Nanomedicine 2 2: 278-302. 2019

Hellberg, S; Silvola, JMU; Liljenbäck, H; Kiugel, M; Eskola, O; Hakovirta, H; Hörkkö, S; Morisson-Iveson, V; Hirani, E; Saukko, P; Ylä-Herttuala, S; Knuuti, J; Saraste, A; Roivainen, A. 2019. Amyloid-Targeting PET Tracer [18F]Flutemetamol Accumulates in Atherosclerotic Plaques Molecules 24 6: 1072. 2019

Hokkanen, K; Tirronen, A; Ylä-Herttuala, S. 2019. Intestinal lymphatic vessels and their role in chylomicron absorption and lipid homeostasis Current opinion in lipidology 30 5: 370-376. 2019

Husso, M; Nissi, MJ; Kuivanen, A; Halonen, P; Tarkia, M; Teuho, J; Saunavaara, V; Vainio, P; Sipola, P; Manninen, H; Ylä-Herttuala, S; Knuuti, J; Töyräs, J. 2019. Quantification of porcine myocardial perfusion with modified dual bolus MRI - a prospective study with a PET reference Bmc medical imaging 19 1: 58. 2019

Hytönen, E; Laurema, A; Kankkonen, H; Miyanohara, A; Kärjä, V; Hujo, M; Laham-Karam, N; Ylä-Herttuala, S. 2019. Bile-duct proliferation as an unexpected side-effect after AAV2-LDLR gene transfer to rabbit liver Scientific reports 9 1: 6934. 2019

Hätinen, OA; Lähteenvuo, JE; Korpela, HJ; Pajula, JJ; Ylä-Herttuala, S. 2019. Isolation of fresh endothelial cells from porcine heart for cardiovascular studies: a new fast protocol suitable for genomic, transcriptomic and cell biology studies BMC Molecular and Cell Biology 20: 32. 2019

Siemelink, Marten A; van der Laan, Sander W; Haitjema, Saskia; van Koeverden, Ian D; Schaap, Jacco; Wesseling, Marian; de Jager, Saskia C A; Mokry, Michal; van Iterson, Maarten; Dekkers, Koen F; Luijk, Rene; Asl, Hassan Foroughi; Michoel, Tom; Björkegren, Johan L M; Aavik, Einari; Ylä-Herttuala, Seppo; de Borst, Gert J; Asselbergs, Folkert W; el Azzouzi, Hamid; den Ruijter, Hester M; et al.. 2018. Smoking is Associated to DNA Methylation in Atherosclerotic Carotid Lesions Circulation. Genomic and precision medicine 11 9: e002030. 2018

Nowak-Sliwinska, P; Alitalo, K; Allen, E; Anisimov, A; Aplin, AC; Auerbach, R; Augustin, HG; Bates, DO; van Beijnum, JR; Bender, RHF; Bergers, G; Bikfalvi, A; Bischoff, J; Böck, BC; Brooks, PC; Bussolino, F; Cakir, B; Carmeliet, P; Castranova, D; Cimpean, AM; et al. [Incl Yläherttuala, Seppo; Nurro, Jussi]. 2018. Consensus guidelines for the use and interpretation of angiogenesis assays Angiogenesis 21 3: 425-532. 2018

Que, X; Hung, MY; Yeang, C; Gonen, A; Prohaska, TA; Sun, X; Diehl, C; Määttä, A; Gaddis, DE; Bowden, K; Pattison, J; MacDonald, JG; Ylä-Herttuala, S; Mellon, PL; Hedrick, CC; Ley, K; Miller, YI; Glass, CK; Peterson, KL; Binder, CJ; et al.. 2018. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice Nature 558: 301-306. 2018

Nikolaev, SI; Vetiska, S; Bonilla, X; Boudreau, E; Jauhiainen, S; Rezai, Jahromi B; Khyzha, N; DiStefano, PV; Suutarinen, S; Kiehl, TR; Mendes Pereira, V; Herman, AM; Krings, T; Andrade-Barazarte, H; Tung, T; Valiante, T; Zadeh, G; Tymianski, M; Rauramaa, T; Ylä-Herttuala, S et al.. 2018. Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain. NEW ENGLAND JOURNAL OF MEDICINE 378 3: 250-261. 2018

Ruotsalainen, Anna-Kaisa; Lappalainen, Jari P; Heiskanen, Emmi; Merentie, Mari; Näpänkangas, Juha; Lottonen-Raikaslehto, Line; Kansanen, Emilia; Adinolfi, Simone; Kaarniranta, Kai; Ylä-Herttuala, Seppo; Jauhiainen, Matti; Pirinen, Eija; Levonen, Anna-Liisa. 2018. Nuclear factor E2-related factor 2 deficiency impairs atherosclerotic lesion development but promotes features of plaque instability in hypercholesterolemic mice CARDIOVASCULAR RESEARCH 2019; 115 1: 243-254. 2018

Ruuth, M; Nguyen, SD; Vihervaara, T; Hilvo, M; Laajala, TD; Kondadi, PK; Gisterå, A; Lähteenmäki, H; Kittilä, T; Huusko, J; Uusitupa, M; Schwab, U; Savolainen, MJ; Sinisalo, J; Lokki, ML; Nieminen, MS; Jula, A; Perola, M; Ylä-Herttula, S; Rudel, L; et al.. 2018. Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths EUROPEAN HEART JOURNAL 39 27: 2562-2573. 2018

Samaranayake, Haritha Dhammika; Olsson, Venla; Kurkipuro, Jere Tuomas; Määttä, Ann-Marie; Stedt, Hanna; Kärkkäinen, Hanna-Riikka; Kaikkonen, Minna U; Taavitsainen, Miia; Vuorio, Taina; Parker, Nigel; Ylä-Herttuala, Seppo. 2018. Up-regulation of Mismatch Repair Pathway by Suicide Gene Therapy: Implications on the use of Temozolomide Treatment in Malignant Glioma Journal of Cancer Science & Therapy 10 8: 214-222. 2018

Schenkwein, Diana; Ylä-Herttuala, Seppo. 2018. Gene Editing of Human Embryos with CRISPR/Cas9: Great Promise Coupled with Important Caveats Molecular therapy 26 3: 659-660. 2018

Ylä-Herttuala, Seppo. 2018. iPSC-Derived Cardiomyocytes Taken to Rescue Infarcted Heart Muscle in Coronary Heart Disease Patients MOLECULAR THERAPY 26 9: 2077. 2018

Silvola, JMU; Li, XG; Virta, J; Marjamäki, P; Liljenbäck, H; Hytönen, JP; Tarkia, M; Saunavaara, V; Hurme, S; Palani, S; Hakovirta, H; Ylä-Herttuala, S; Saukko, P; Chen, Q; Low, PS; Knuuti, J; Saraste, A; Roivainen, A. 2018. Aluminum fluoride-18 labeled folate enables in vivo detection of atherosclerotic plaque inflammation by positron emission tomography Scientific Reports 8 1: 9720. 2018

Tirronen, Annakaisa; Vuorio, Taina; Kettunen, Sanna; Hokkanen, Krista; Ramms, Bastian; Niskanen, Henri; Laakso, Hanne; Kaikkonen, Minna U; Jauhiainen, Matti; Gordts, Philip LSM; Ylä-Herttuala, Seppo. 2018. Deletion of Lymphangiogenic and Angiogenic Growth Factor VEGF-D Leads to Severe Hyperlipidemia and Delayed Clearance of Chylomicron Remnants Arteriosclerosis thrombosis and vascular biology 38 10: 2327-2337. 2018

van Zuydam, Natalie R; Ahlqvist, Emma; Sandholm, Niina; Deshmukh, Harshal; Rayner N, William; bdalla, Moustafa; Ladenvall, Claes; Ziemek, Daniel; Fauman, Eric; Robertson, Neil R; McKeigue, Paul M; Valo, Erkka; Forsblom, Carol; Harjutsalo, Valma; Perna, Annalisa; Rurali, Erica; Marcovecchio M, Loredana; Igo, Robert P Jr; Summit Consortium; et al. (incl. Ylä-Herttuala, S; Laakso, M). 2018. A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes Diabetes 67 7: 1414-1427. 2018

Vuorio, Taina; Ylä-Herttuala, Elias; Laakkonen, Johanna P; Laidinen, Svetlana; Liimatainen, Timo; Ylä-Herttuala, Seppo. 2018. Downregulation of VEGFR3 signaling alters cardiac lymphatic vessel organization and leads to a higher mortality after acute myocardial infarction Scientific Reports 8: 16709. 2018

Ylä-Herttuala, Seppo. 2018. All Eyes and Ears for Gene Therapy Molecular therapy 26 8: 1867. 2018

Ylä-Herttuala, Seppo. 2018. CRISPR/Cas9 and p53: An Odd Couple Requiring Relationship Management MOLECULAR THERAPY 26 12: 2711. 2018

Ylä-Herttuala, Seppo. 2018. Uusi geenihoito tulossa uusiutuneen hoitoresistentin akuutin lymfoblastileukemian hoitoon Duodecim 134 2: 104-105. 2018

Zimmermann, Wolfram-Hubertus; Yla-Herttuala, Seppo; Hajjar, Roger J. 2018. Highlighting the Field of Cardiovascular Regenerative Medicine MOLECULAR THERAPY 26 7: 1595. 2018

Nieminen, Tiina; Scott, Tristan A; Lin, Feng-Mao; Chen, Zhen; Yla-Herttuala, Seppo; Morris, Kevin V. 2018. Long Non-Coding RNA Modulation of VEGF-A during Hypoxia Non-Coding RNA 4 4: 34. 2018

Nikolaev, Sergey I; Vetiska, Sandra; Bonilla, Ximena; Boudreau, Emilie; Jauhiainen, Suvi; Jahromi, Behnam Rezai; Khyzha, Nadiya; DiStefano, Peter V; Suutarinen, Santeri; Kiehl, Tim-Rasmus; Pereira, Vitor Mendes; Herman, Alexander M; Krings, Timo; Andrade-Barazarte, Hugo; Tung, Takyee; Valiante, Taufik; Zadeh, Gelareh; Tymianski, Mike; Rauramaa, Tuomas; Ylä-Herttuala, Seppo; et al.. 2018. Verisuonten seinämien somaattiset mutaatiot aivojen valtimo-laskimoepämuodostumien aiheuttajina Duodecim 134 3: 298. 2018

Hellberg, Sanna; Liljenbäck, Heidi; Eskola, Olli; Morisson-Iveson, Veronique; Morrison, Matthew; Trigg, William; Saukko, Pekka; Ylä-Herttuala, Seppo; Knuuti, Juhani; Saraste, Antti; Roivainen, Anne. 2018. Positron Emission Tomography Imaging of Macrophages in Atherosclerosis with 18F-GE-180, a Radiotracer for Translocator Protein (TSPO) Contrast Media and Molecular Imaging 2018: 9186902. 2018

Moreau, Pierre R; Örd, Tiit; Downes, Nicholas L; Niskanen, Henri; Bouvy-Liivrand, Maria; Aavik, Einari; Ylä-Herttuala, Seppo; Kaikkonen, Minna U. 2018. Transcriptional Profiling of Hypoxia-Regulated Non-coding RNAs in Human Primary Endothelial Cells Frontiers in cardiovascular medicine 5 159: 12. 2018

Gurzeler, Erika; Aavik, Einari; Laine, Anssi; Valkama, Teemu; Niskanen, Henri; Huusko, Jenni; Kaikkonen, Minna U; Ylä-Herttuala, Seppo. 2018. Therapeutic effects of rosuvastatin in hypercholesterolemic prediabetic mice in the absence of low density lipoprotein receptor Biochimica et biophysica acta: general subjects 2019; 1863 2: 481-490. 2018

Merentie, Mari; Rissanen, Riina; Lottonen-Raikaslehto, Line; Huusko, Jenni; Gurzeler, Erika; Turunen, Mikko P; Holappa, Lari; Mäkinen, Petri; Ylä-Herttuala, Seppo. 2018. Doxycycline modulates VEGF-A expression: Failure of doxycycline-inducible lentivirus shRNA vector to knockdown VEGF-A expression in transgenic mice. PLOS ONE 13 1: e0190981. 2018

Belt, H; Koponen, JK; Kekarainen, T; Puttonen, KA; Mäkinen, PI; Niskanen, H;, Oja, J; Wirth, G; Koistinaho, J; Kaikkonen, MU; Ylä-Herttuala, S. 2018. Temporal Dynamics of Gene Expression During Endothelial Cell Differentiation From Human iPS Cells: A Comparison Study of Signalling Factors and Small Molecules. Frontiers in cardiovascular medicine 5: 16. 2018

Blanco, F; Heinonen, SE; Gurzeler, E; Berglund, LM; Dutius Andersson, AM; Kotova, O; Jönsson-Rylander, AC; Ylä-Herttuala, S; Gomez, MF. 2018. In vivo inhibition of nuclear factor of activated T-cells leads to atherosclerotic plaque regression in IGF-II/LDLR-/-ApoB100/100 mice DIABETES AND VASCULAR DISEASE RESEARCH 15 4: 302-313. 2018

Büning, Hildegard; Griesenbach, Uta; Fehse, Boris; Ylä-Herttuala, Seppo; Anagnou, Nicholas P; van Beusechem, Victor; Raya, Angel; Verhoeyen, Els. 2018. Consensus Statement of European Societies of Gene and Cell Therapy on the Reported Birth of Genome-Edited Babies in China Human gene therapy 29 12: 1337-1338. 2018

Caporali, A; Bäck, M; Daemen, MJ; Hoefer, IE; Jones, EA; Lutgens, E; Matter, CM; Bochaton-Piallat, ML; Siekmann, AF; Sluimer, JC; Steffens, S; Tuñón, J; Vindis, C; Wentzel, JJ; Ylä-Herttuala, S; Evans, PC. 2018. Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working group on Atherosclerosis and Vascular Biology Cardiovascular research 114 11: 1411-1421. 2018

Downes, Nicholas L; Laham-Karam, Nihay; Kaikkonen, Minna U; Ylä-Herttuala, Seppo. 2018. Differential but Complementary HIF1[alfa] and HIF2[alfa] Transcriptional Regulation MOLECULAR THERAPY 26 7: 1735-1745. 2018

Duplisea, Jonathan J; Mokkapati, Sharada; Plote, Devin; Schluns, Kimberley S; McConkey, David J; Yla-Herttuala, Seppo; Parker, Nigel R; Dinney, Colin P. 2018. The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside World journal of urology 2019; 37 10: 2041-2049. 2018

Groppa, E; Brkic, S; Uccelli, A; Wirth, G; Korpisalo-Pirinen, P; Filippova, M; Dasen. B; Sacchi, V; Muraro, MG; Trani, M; Reginato, S; Gianni-Barrera, R; Ylä-Herttuala, S; Banfi, A. 2018. EphrinB2/EphB4 signaling regulates non-sprouting angiogenesis by VEGF. EMBO REPORTS 19 4: e45054. 2018

Banfi, Andrea; Holnthoner, Wolfgang; Martino, Mikael M; Ylä-Herttuala, Seppo. 2018. Editorial: Vascularization for Regenerative Medicine Frontiers in bioengineering and biotechnology 6: 175. 2018

Laakso, Hanne; Wirth, Galina; Korpisalo, Petra; Ylä-Herttuala, Elias; Michaeli, Shalom; Ylä-Herttuala, Seppo; Liimatainen, Timo. 2018. T-2, T-1rho and T-RAFF4 detect early regenerative changes in mouse ischemic skeletal muscle Nmr in biomedicine 31 5: e3909. 2018

Huikuri, Heikki; Hartikainen, Juha; Ylä-Herttuala, Seppo; Sinisalo, Juha; Airaksinen, Juhani; Nikus, Kjell. 2018. Kardiologian tutkimustoiminta Suomessa viimeisten 10 vuoden aikana Sydänääni: Suomen kardiologisen seuran lehti 29 1A: 207-211. 2018

Hytönen, Jarkko P; Taavitsainen, Jouni; Laitinen, Johannes T T; Partanen, Anna; Alitalo, Kari; Leppänen, Olli; Ylä-Herttuala, Seppo. 2018. Local adventitial anti-angiogenic gene therapy reduces growth of vasa-vasorum and in-stent restenosis in WHHL rabbits JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY 121: 145-154. 2018

Hytönen, Jarkko P; Taavitsainen, Jouni; Tarvainen, Santeri; Ylä-Herttuala, Seppo. 2018. Biodegradable coronary scaffolds - their future and clinical and technological challenges CARDIOVASCULAR RESEARCH 114 8: 1063-1072. 2018

Kokki, Emmi; Karttunen, Tommi; Olsson, Venla; Kinnunen, Kati; Ylä-Herttuala, Seppo. 2018. Human Vascular Endothelial Growth Factor A165 Expression Induces the Mouse Model of Neovascular Age-Related Macular Degeneration Genes 9 9: E438. 2018

Korhonen, Matti; Keränen, Mikko; Vettenranta, Kim; Leppä, Sirpa; Ylä-Herttuala, Seppo; Porkka, Kimmo. 2018. Syövän immunologinen täsmähoito geneettisesti muokatuilla T-soluilla Duodecim 134 16: 1592-1599. 2018

Krause, M; Rak-Raszewska, A; Naillat, F; Saarela, U; Schmidt, C; Ronkainen, VP; Bart, G; Ylä-Herttuala, S; Vainio, SJ. 2018. Exosomes as secondary inductive signals involved in kidney organogenesis. Journal of Extracellular Vesicles 7 1: 1422675. 2018

Huang, Jun; Kelly, Ciaran P; Bakirtzi, Kyriaki; Villafuerte Gálvez, Javier A; Lyras, Dena; Mileto, Steven J; Larcombe, Sarah; Xu, Hua; Yang, Xiaotong; Shields, Kelsey S; Zhu, Weishu; Zhang, Yi; Goldsmith, Jeffrey D; Patel, Ishan J; Hansen, Joshua; Huang, Meijin; Yla-Herttuala, Seppo; Moss, Alan C; Paredes-Sabja, Daniel; Pothoulakis, Charalabos; et al.. 2018. Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis Nature microbiology 2019; 4 2: 269-279. 2018

Tuppurainen L, Sallinen H, Karvonen A, Valkonen E, Laakso H, Liimatainen T, Hytönen E, Hämäläinen K, Kosma V-M, Anttila M, Ylä-Herttuala S. 2017. Combined gene therapy using AdsVEGFR2 and AdsTie2 with chemotherapy reduces the growth of human ovarian cancer and formation of ascites in mice. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 27 5: 879-886. 2017

Turunen Tiia A, Ylä-Herttuala Seppo, Turunen Mikko P. 2017. Enhancing Angiogenesis in Mice by VEGF-Targeting Small Activating RNAs. In: Long-Cheng Li (ed.) RNA Activation. Springer. Advances in Experimental Medicine and Biology 983. s. 195-205. 2017

Turunen TA, Väänänen M-A, Ylä-Herttuala S. 2017. Epigenomics. In: Sawyer Douglas, Vasan Ramachandran (ed.) Encyclopedia of Cardiovascular Research and Medicine. Elsevier. s. 258-265. 2017

Niittykoski Minna, von und zu Fraunberg Mikael, Martikainen Miika, Rauramaa, Immonen Arto, Koponen Susanna, Leinonen Ville, Vähä-Koskela Markus, Zhang Qiwei, Kühnel Florian, Mei Ya-Fang, Ylä-Herttuala Seppo, Jääskeläinen Juha E, Hinkkanen Ari. 2017. Immunohistochemical Characterization and Sensitivity to Human Adenovirus Serotypes 3, 5, and 11p of New Cell Lines Derived from Human Diffuse Grade II to IV Gliomas. Translational Oncology 10 5: 772-779. 2017

Toivanen Pyry I, Nieminen Tiina, Laakkonen Johanna P, Heikura Tommi, Kaikkonen Minna U, Ylä-Herttuala Seppo. 2017. Snake venom VEGF Vammin induces a highly efficient angiogenic response in skeletal muscle via VEGFR-2/NRP specific signaling. Scientific Reports 7: 5525. 2017

Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G et al. 2017. Intravesical rAd-IFN[alfa]/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. JOURNAL OF CLINICAL ONCOLOGY 35 30: 3410-3416. 2017

Positron emission tomography tracer [68GA]NODAGA-EXENDIN-4 detects glucagon-like peptide-1 receptor expression in mouse atherosclerotic vascular lesions. Ståhle M, Hellberg S, Virta J, Liljenbäck H, Metsälä O, Jauhiainen M, Saukko P, Ylä-Herttuala S, Nuutila P, Knuuti J, Saraste A, Roivainen A. Atherosclerosis. 2017. 2017

van Lith, SAM; van den Brand, D; Wallbrecher, R; Wübbeke, L; van Duijnhoven, SMJ; Mäkinen, PI; Hoogstad-van, Evert JS; Massuger, L; Ylä-Herttuala, S; Brock, R; Leenders, WPJ. 2017. The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS 2018; 124: 63-72. 2017

Valkama, AJ; Leinonen, HM; Lipponen, EM; Turkki, V; Malinen, J; Heikura, T; Ylä-Herttuala, S; Lesch, HP. 2017. Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor GENE THERAPY 2018; 25: 39-46. 2017

Ylä-Herttuala S. 2017. ESGCT 2017 in Berlin: Clear Steps Forward MOLECULAR THERAPY 25 12: 2599. 2017

Vuorio Taina, Tirronen Annakaisa, Ylä-Herttuala Seppo. 2017. Cardiac Lymphatics - A New Avenue for Therapeutics? Trends in endocrinology and metabolism 28 4: 285-296. 2017

Wennink JWH, Liu Y, Mäkinen PI, Setaro F, de la Escosura A, Bourajjaj M, Lappalainen JP, Holappa LP, van den Dikkenberg JB, Al Fartousi M, Trohopoulos PN, Ylä-Herttuala S, Torres T, Hennink WE, van Nostrum CF. 2017. Macrophage selective photodynamic therapy by meta-tetra(hydroxyphenyl)chlorin loaded polymeric micelles : a possible treatment for cardiovascular diseases. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 107: 112-125. 2017

Ylä-Herttuala S, Baker AH. 2017. Cardiovascular gene therapy : past, present, and future. MOLECULAR THERAPY 25 5: 1095-1106. 2017

Ylä-Herttuala S, Bridges C, Katz MG, Korpisalo P. 2017. Angiogenic gene therapy in cardiovascular diseases: dream or vision?. EUROPEAN HEART JOURNAL 38 18: 1365-1371. 2017

Ylä-Herttuala Seppo. 2017. Bumps in the Road for Commercial Gene Therapy for Rare Diseases. MOLECULAR THERAPY 25 10: 2225. 2017

Ylä-Herttuala Seppo. 2017. Call for Papers in the Area of Cardiovascular Regenerative Medicine MOLECULAR THERAPY 25 9: 1989. 2017

Ylä-Herttuala Seppo. 2017. Geenihoidot: haasteita ja suuria lupauksia. In: Jokela Maarit, Oja-Leikas Mirkka, Rova Meri (ed.) Kiehtovat geenit: Mihin geenititetoa käytetään?. Duodecim. s. 88-94. 2017

Ylä-Herttuala Seppo. 2017. The Pharmacology of Gene Therapy. MOLECULAR THERAPY 25 8: 1731-1732. 2017

Niskanen, Henri; Tuszynska, Irina; Zaborowski, Rafal; Heinäniemi, Merja; Ylä-Herttuala, Seppo; Wilczynski, Bartek; Kaikkonen, Minna U. 2017. Endothelial cell differentiation is encompassed by changes in long range interactions between inactive chromatin regions NUCLEIC ACIDS RESEARCH 2018; 46 4: 1724-1740. 2017

Lindgren A, Anttila M, Rautiainen S, Arponen O, Kivelä A, Mäkinen P, Härmä K, Hämäläinen K, Kosma V-M, Ylä-Herttuala S, Vanninen R, Sallinen H. 2017. Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRI EUROPEAN RADIOLOGY 27 9: 4002-4012. 2017

Naumenko N, Huusko J, Tuomainen T, Koivumäki JT, Merentie M, Gurzeler E, Alitalo K, Kivelä R, Ylä-Herttuala S, Tavi P. 2017. Vascular Endothelial Growth Factor-B Induces a Distinct Electrophysiological Phenotype in Mouse Heart. Frontiers in Physiology 8: 373. 2017

Kaikkonen Minna U, Halonen Paavo, Liu Oscar Hsin-Fu, Turunen Tiia A, Pajula Juho, Moreau Pierre, Selvarajan Ilakya, Tuomainen Tomi, Aavik Einari, Tavi Pasi, Ylä-Herttuala Seppo. 2017. Genome-Wide Dynamics of Nascent Noncoding RNA Transcription in Porcine Heart After Myocardial Infarction Circulation: Cardiovascular Genetics 10 3: e001702. 2017

Mathur A, Fernández-Avilés F, Dimmeler S, Hauskeller C, Janssens S, Menasche P, Wojakowski W, Martin JF, Zeiher A, the BAMI Investigators. 2017. The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: update 2016. EUROPEAN HEART JOURNAL 38 39: 2930-2935. 2017

Effects of linagliptin intervention on atherosclerotic plaque inflammation and 18F-FDG uptake in a mouse model of type 2 diabetes. Virta J, Silvola J, Hellberg S, Ståhle M, Liljenbäck H, Ylä-Herttuala S, Huusko J, Nuutila P, Knuuti J, Roivainen A, Saraste A. Atherosclerosis. 2017. 2017

Fernández-Avilés Francisco, Sanz-Ruiz Ricardo, Climent Andreu M, Badimon Lina, Bolli Roberto, Charron Dominique, Fuster Valentin, Janssens Stefan, Kastrup Jens, Kim Hyo-Soo, Lüscher Thomas F, Martin John F, Menasché Philippe, Simari Robert D, Stone Gregg W, Terzic Andre, Willerson James T, Wu Joseph C, Broughton Kathleen, DiFede Darcy L et al incl. Ylä-Herttuala Seppo. 2017. Global position paper on cardiovascular regenerative medicine. EUROPEAN HEART JOURNAL 38 33: 2532-2546. 2017

Grönman M, Tarkia M, Kiviniemi T, Halonen P, Kuivanen A, Savunen T, Tolvanen T, Teuho J, Käkelä M, Metsälä O, Pietilä M, Saukko P, Ylä-Herttuala S, Knuuti J, Roivainen A, Saraste A. 2017. Imaging of [alpha]vß3 integrin expression in experimental myocardial ischemia with [68Ga]NODAGA-RGD positron emission tomography. Journal of Translational Medicine 15: 144. 2017

Hartikainen Juha, Hassinen Iiro, Hedman Antti, Kivelä Antti, Saraste Antti, Knuuti Juhani, Husso Minna, Mussalo Hanna, Hedman Marja, Rissanen Tuomas T, Toivanen Pyry, Heikura Tommi, Witztum Joseph, Tsimikas Sotirios, Ylä-Herttuala Seppo. 2017. Lupaavia tuloksia sepelvaltimotaudin geenihoidosta. DUODECIM 133 17: 1613. 2017

Hellberg S, Sippola S, Liljenbäck H, Virta J, Silvola JMU, Ståhle M, Savisto N, Metso J, Jauhiainen M, Saukko P, Ylä-Herttuala S, Nuutila P, Knuuti J, Roivainen A, Saraste A. 2017. Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [18F]FDG uptake in Ldlr-/-Apob100/100 mice. ATHEROSCLEROSIS 263: 369-376. 2017

Kaartinen T, Luostarinen A, Maliniemi P, Keto J, Arvas M, Belt H, Koponen J, Loskog A, Mustjoki S, Porkka K, Ylä-Herttuala S, Korhonen M. 2017. Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion. Cytotherapy 19 6: 689-702. 2017

Hartikainen J, Hassinen I, Hedman A, Kivelä A, Saraste A, Knuuti J, Husso M, Mussalo H, Hedman M, Rissanen TT, Toivanen P, Heikura T, Witztum JL, Tsimikas S, Ylä-Herttuala S. 2017. Adenoviral intramyocardial VEGF-DdeltaNdeltaC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up. EUROPEAN HEART JOURNAL 38 33: 2547-2555. 2017

Kalesnykas G, Kokki E, Alasaarela L, Lesch HP, Tuulos T, Kinnunen K, Uusitalo H, Airenne K, Ylä-Herttuala S. 2017. Comparative Study of Adeno-associated Virus, Adenovirus, Baculovirus and Lentivirus Vectors for Gene Therapy of the Eyes. CURRENT GENE THERAPY 17 3: 235-247. 2017

Durga Devi T, Babu M, Mäkinen P, Kaikkonen M, Heinaniemi M, Laakso H, Ylä-Herttuala E, Rieppo L, Liimatainen T, Naumenko N,Tavi P, Ylä-Herttuala S. 2017. Aggravated post-infarct heart failure in type 2 diabetes is associated with impaired mitophagy and exaggerated inflammasome activation. AMERICAN JOURNAL OF PATHOLOGY 187 12: 2659-2673. 2017

Khan, Muhammad Arsalan; Laakso, Hanne; Laidinen, Svetlana; Kettunen, Sanna; Heikura, Tommi; Ylä-Herttuala, Seppo; Liimatainen, Timo. 2017. The follow-up of progressive hypertrophic cardiomyopathy using magnetic resonance rotating frame relaxation times NMR IN BIOMEDICINE 2018; 31 2: e3871. 2017

Lähteenvuo Johanna, Ylä-Herttuala Seppo. 2017. Advances and Challenges in Cardiovascular Gene Therapy. HUMAN GENE THERAPY 28 11: 1024-1032. 2017

Lottonen-Raikaslehto L, Rissanen R, Gurzeler E, Merentie M, Huusko J, Schneider JE, Liimatainen T, Ylä-Herttuala S. 2017. Left ventricular remodeling leads to heart failure in mice with cardiac-specific overexpression of VEGF-B167: echocardiography and magnetic resonance imaging study. Physiological Reports 5 6: e13096. 2017

Mathur A, Arnold R, Assmus B, Bartunek J, Belmans A, Bönig H, Crea F, Dimmeler S, Dowlut S, Fernández-Avilés F, Galiñanes M, Garcia-Dorado D, Hartikainen J, Hill J, Hogardt-Noll A, Homsy C, Janssens S, Kala P, Kastrup J, Martin J et al.. 2017. The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial. EUROPEAN JOURNAL OF HEART FAILURE 19 11: 1545-1550. 2017

Lee, JS; Han, P; Song, E; Kim, D; Lee, H; Labowsky, M; Taavitsainen, J; Ylä-Herttuala, S; Hytönen, J; Gülcher, M; Perampaladas, K; Sinusas, AJ; Martin, J; Mathur, A; Fahmy, TM. 2017. Magnetically Coated Bioabsorbable Stents for Renormalization of Arterial Vessel Walls after Stent Implantation NANOLETTERS 2018; 18 1: 272-281. 2017

Laham-Karam, Nihay; Laitinen, Pia; Turunen, Tiia A; Ylä-Herttuala, Seppo. 2017. Activating the Chromatin by Noncoding RNAs ANTIOXIDANTS AND REDOX SIGNALING 2018; 29 9: 813-831. 2017

Kivelä AM, Huusko J, Gurzeler E, Laine A, Dijkstra MH, Dragneva G, Andersen CB, Moestrup SK, Ylä-Herttuala S. 2017. High Plasma Lipid Levels Reduce Efficacy of Adenovirus-Mediated Gene Therapy. Scientific Reports 7 386: 1-8. 2017

Mutikainen Maija, Tuomainen Tomi, Naumenko Nikolay, Huusko Jenni, Smirin Boris, Laidinen S, Kokki K, Hynynen H, Ylä-Herttuala S, Heinäniemi M, Ruas JL, Tavi P. 2016. Peroxisome Proliferator-activated Receptor-gamma Coactivator 1 alfa1 Induces a Cardiac Excitation-contraction Coupling Phenotype Without Metabolic Remodelling. JOURNAL OF PHYSIOLOGY (CAMBRIDGE) 594 23: 7049-7071. 2016

Ylä-Herttuala, S, Wartiowaara K. 2016. Geeni- ja soluterapia. In: Aittomäki K, Moilanen J, Perola M (ed.) Lääketieteellinen genetiikka. Duodecim. s. 393-404. 2016

Ylä-Herttuala Seppo. 2016. Onkolyyttinen virusgeeniterapia tulossa metastasoituneen melanooman hoitoon. DUODECIM 132 4: 297-8. 2016

Ylä-Herttuala Seppo. 2016. CardioPulse: Progress in gene therapy for cardiovascular disease. EUROPEAN HEART JOURNAL 37 14: 1093. 2016

Ylä-Herttuala Seppo. 2016. ADA-SCID Gene Therapy Endorsed By European Medicines. MOLECULAR THERAPY 2017; 24 6: 1013-1014. 2016

van Lith SA, Roodink I, Verhoeff JJ, Mäkinen PI, Lappalainen JP, Ylä-Herttuala S, Raats J, van Wijk E, Roepman R, Letteboer SJ, Verrijp K, Leenders WP. 2016. In vivo phage display screening for tumor vascular targets in glioblastoma identifies a llama nanobody against dynactin-1-p150Glued. Oncotarget 7 44: 71594-71607. 2016

Turunen Tytteli AK, Kurkipuro Jere, Heikura Tommi, Vuorio Taina, Hytönen Elisa, Izsvák Zsuzsanna, Ylä-Herttuala Seppo. 2016. Sleeping Beauty transposon vectors in liver directed gene delivery of LDLR and VLDLR for gene therapy of familial hypercholesterolemia. MOLECULAR THERAPY 24 3: 620-635. 2016

Silvola Johanna MU, Virtanen Helena, Siitonen Riikka, Hellberg Sanna, Liljenbäck Heidi, Metsälä Olli, Ståhle Mia, Saanijoki Tiina, Käkelä Meeri, Hakovirta Harri, Ylä-Herttuala Seppo, Saukko Pekka, Jauhiainen Matti, Veres Tibor Z, Jalkanen Sirpa, Knuuti Juhani, Saraste Antti, Roivainen Anne. 2016. Leukocyte trafficking-associated vascular adhesion protein 1 is expressed and functionally active in atherosclerotic plaques. Scientific Reports 6: 35089. 2016

Seki T, Hosaka K, Lim S, Fischer C, Honek J, Yang Y, Andersson P, Nakamura M, Näslund E, Ylä-Herttuala S, Sun M, Iwamoto H, Li X, Liu Y, Samani NJ, Cao Y. 2016. Endothelial PDGF-CC regulates angiogenesis-dependent thermogenesis in beige fat. Nature Communications 7: 12152. 2016

Schenkwein D, Ylä-Herttuala S. 2016. Development of lentiviral vectors for targeted integration and protein delivery. In: Maurizio Federico (ed.) Lentiviral Vectors and Exosomes as Gene and Protein Delivery Tools. Springer science+business media. Methods in Molecular Biology 1448, Part III. s. 185-198. 2016

Ollikainen Eliisa, Tulamo Riikka, Lehti Satu, Lee-Rueckert Miriam, Hernesniemi Juha, Niemela Mika, Ylä-Herttuala Seppo, Kovanen Petri T, Frösen Juhana. 2016. Smooth muscle cell foam cell formation, apolipoproteins, and ABCA1 in intracranial aneurysms: implications for lipid accumulation as a promoter of aneurysm wall rupture. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (LAWRENCE KS) 75 7: 689-699. 2016

Nurro Jussi, Halonen Paavo J, Kuivanen Antti, Tarkia Miikka, Saraste Antti, Honkonen Krista, Lähteenvuo Johanna, Rissanen Tuomas T, Knuuti Juhani, Ylä-Herttuala Seppo. 2016. AdVEGF-B186 and AdVEGF-D(Delta)N(Delta)C induce angiogenesis and increase perfusion in porcine myocardium. HEART [Epub ahead of print 12 May 2016]. 2016

Ylä-Herttuala Seppo. 2016. Täsmähoidot tuovat uutta toivoa monille syöpäpotilaille. KANSANTERVEYS - 5: -. 2016

Muhl L, Moessinger C, Adzemovic MZ, Dijkstra MH, Nilsson I, Zeitelhofer M, Hagberg CE, Huusko J, Falkevall A, Ylä-Herttuala S, Eriksson U. 2016. Expression of vascular endothelial growth factor (VEGF)-B and its receptor (VEGFR1) in murine heart, lung and kidney. CELL AND TISSUE RESEARCH 365 1: 51-63. 2016

Gallini R, Huusko J, Ylä-Herttuala S, Betsholtz C, Andrae J. 2016. Isoform-Specific Modulation of Inflammation Induced by Adenoviral Mediated Delivery of Platelet-Derived Growth Factors in the Adult Mouse Heart. PLOS ONE 11 8: e0160930. 2016

Laakkonen Johanna P, Ylä-Herttuala Seppo. 2016. Animal Models of Gene Therapy for Cardiovascular Disease. In: David T. Curiel (ed.) Adenoviral Vectors for Gene Therapy. Elsevier. s. 691-705. 2016

Cartier-Lacave N, Ali R, Ylä-Herttuala S, Kato K, Baetschi B, Lovell-Badge R, Naldini L, Thrasher A. 2016. Debate on Germline Gene Editing. HUMAN GENE THERAPY METHODS 27 4: 135-142. 2016

David Anna, Ashcroft Richard, Ylä-Herttuala Seppo, Hecher Kurt, Figueras Francesc, Marsal Karel, Sleigh Sara, Brookes Jocelyn, Campbell David. 2016. Does Vascular Endothelial Growth Factor Gene Therapy Safely Improve Outcome in Severe Early-Onset Fetal Growth Restriction? (EVERREST). Human Gene Therapy Clinical Development June 2015, 26 2: 82-84. 2016

Frederickson RM, Moghimi SM, Wagner E, Yla-Herttuala S. 2016. Call for papers: Nanoparticle Development and Applications in Cellular and Molecular Therapies. MOLECULAR THERAPY 2017; 24 8: 1334-1335. 2016

Frederickson Robert M, Ylä-Herttuala Seppo. 2016. Writing the Next Chapter for the Molecular Therapy Family of Journals. MOLECULAR THERAPY 24 10: 1707. 2016

Hassinen Iiro, Kivelä Antti, Hedman Antti, Saraste Antti, Knuuti Juhani, Hartikainen Juha, Ylä-Herttuala Seppo. 2016. Intramyocardial Gene Therapy Directed to Hibernating Heart Muscle Using a Combination of Electromechanical Mapping and Positron Emission Tomography. HUMAN GENE THERAPY 27 10: 830-834. 2016

Hellberg S, Silvola JM, Kiugel M, Liljenbäck H, Metsälä O, Viljanen T, Metso J, Jauhiainen M, Saukko P, Nuutila P, Ylä-Herttuala S, Knuuti J, Roivainen A, Saraste A. 2016. Type 2 diabetes enhances arterial uptake of choline in atherosclerotic mice: an imaging study with positron emission tomography tracer 18F-fluoromethylcholine. CARDIOVASCULAR DIABETOLOGY [ONLINE: HTTP://WWW.CARDIAB.COM/] 15: 26. 2016

Hellberg S, Silvola JM, Kiugel M, Liljenbäck H, Savisto N, Li XG, Thiele A, Lehmann L, Heinrich T, Vollmer S, Hakovirta H, Laine VJ, Ylä-Herttuala S, Knuuti J, Roivainen A, Saraste A. 2016. 18-kDa translocator protein ligand 18F-FEMPA: Biodistribution and uptake into atherosclerotic plaques in mice. JOURNAL OF NUCLEAR CARDIOLOGY 2017; 24 3: 862-871. 2016

Hytönen J, Leppänen O, Braesen JH, Schunck W-H, Mueller D, Jung F, Mrowietz C, Jastroch M, Von Bergwelt-Baildon M, Kappert K, Heuser A, Drenckhahn J-D, Pieske B, Thierfelder L, Ylä-Herttuala S, Blaschke F. 2016. Activation of peroxisome proliferator-activated receptor-delta as novel therapeutic strategy to prevent in-stent restenosis and stent thrombosis. ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY 36 8: 1534-1548. 2016

Korhonen EA, Lampinen A, Giri H, Anisimov A, Kim M, Allen B, Fang S, D'Amico G, Sipilä TJ, Lohela M, Strandin T, Vaheri A, Ylä-Herttuala S, Koh GY, McDonald DM, Alitalo K, Saharinen P.. 2016. Tie1 controls angiopoietin function in vascular remodeling and inflammation. JOURNAL OF CLINICAL INVESTIGATION 126 9: 3495-3510. 2016

Laakkonen Johanna P, Lappalainen Jari P, Theelen Thomas L, Toivanen Pyry I, Nieminen Tiina, Jauhiainen Suvi,Kaikkonen Minna U, Sluimer Judith C, Ylä-Herttuala Seppo. 2016. Differential regulation of angiogenic cellular processes and claudin-5 by histamine and VEGF via PI3K-signaling, transcription factor SNAI2 and interleukin-8. Angiogenesis [Epub ahead of print 21 Nov 2016]: 1-16. 2016

Tuuminen Raimo, Dashkevich Alexey, Keränen Mikko AI, Raissadati Alireza, Krebs Rainer, Jokinen Janne J, Arnaudova Ralica, Rouvinen Eeva, Ylä-Herttuala Seppo, Nykänen Antti I, Lemström Karl B. 2015. Verihiutalekasvutekijä B suojaa rotan siirtosydäntä iskemia-reperfuusiovauriolta. DUODECIM 131 19: 1821. 2015

Stedt H, Samaranayake H, Kurkipuro J, Wirth G, Christiansen LS, Vuorio T, Määttä A-M, Piškur J, Ylä-Herttuala S. 2015. Tomato thymidine kinase-based suicide gene therapy for malignant glioma - an alternative for Herpes Simplex virus-1 thymidine kinase. CANCER GENE THERAPY 22: 130-137. 2015

Sunkari Vivekananda Gupta, Lind Folke, Botusan Ileana Ruxandra, Kashif Abad, Liu Zhao-Jun, Ylä-Herttuala Seppo, Brismar Kerstin, Velazquez Omaida, Catrina Sergiu-Bogdan. 2015. Hyperbaric oxygen therapy activates hypoxia-inducible factor 1 (HIF-1), which contributes to improved wound healing in diabetic mice. Wound Repair and Regeneration 23 1: 98-103. 2015

Tervala Tomi V, Hartiala Pauliina, Tammela Tuomas, Visuri Mikko T, Ylä-Herttuala Seppo, Alitalo Kari, Saarikko Anne M. 2015. Growth factor therapy and lymph node graft for lymphedema. Journal of Surgical Research 196 1: 200-207. 2015

Theelen Thomas L, Lappalainen Jari P, Sluimer Judith C, Gurzeler Erika, Cleutjens Jack P, Gijbels Marion J, Biessen Erik AL, Daemen Mat JAP, Alitalo Kari, Ylä-Herttuala Seppo. 2015. Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice. ATHEROSCLEROSIS 241 2: 297-304. 2015

Tuuminen R, Dashkevich A, Keränen MA, Raissadati A, Krebs R, Jokinen JJ, Arnaudova R, Rouvinen E, Ylä-Herttuala S, Nykänen AI, Lemström KB. 2015. Platelet-Derived Growth Factor-B Protects Rat Cardiac Allografts From Ischemia-reperfusion Injury. TRANSPLANTATION [epub ahead of print Sep 14 2015]: -. 2015

Ylä-Herttuala Seppo. 2015. The Molecular Therapy Family: Past, Present, and Future. MOLECULAR THERAPY 23 1: 1. 2015

Visuri Mikko T, Honkonen Krista M, Hartiala Pauliina, Tervala Tomi V, Halonen Paavo J, Junkkari Heikki, Knuutinen Nina, Ylä-Herttuala Seppo, Alitalo Kari K, Saarikko Anne M. 2015. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study. Angiogenesis 18 3: 313-326. 2015

Ylä-Herttuala Seppo. 2015. Foreword: Gene and Cell Therapy Matures to the Clinics: Nancy Smyth Templeton, Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 4th Edition. xi-xii. 2015

Ylä-Herttuala Seppo. 2015. From the Impact Factor to DORA and the Scientific Content of Articles. MOLECULAR THERAPY 23 4: 609. 2015

Ylä-Herttuala Seppo. 2015. Gene Therapy for Heart Failure: Back to the Bench. MOLECULAR THERAPY 23 10: 1551-1552. 2015

Ylä-Herttuala Seppo. 2015. Gene Therapy in Nordic Countries. HUMAN GENE THERAPY 26 8: 473-474. 2015

Ylä-Herttuala Seppo. 2015. Glybera's Second Act: The Curtain Rises on the High Cost of Therapy. MOLECULAR THERAPY 23 2: 217-218. 2015

Nieminen Tiina, Toivanen Pyry I, Laakkonen Johanna P, Heikura Tommi, Kaikkonen Minna U, Airenne Kari J, Ylä-Herttuala Seppo. 2015. Slit2 modifies VEGF-induced angiogenic responses in rabbit skeletal muscle via reduced eNOS activity. CARDIOVASCULAR RESEARCH 107 2: 267-276. 2015

Merentie M, Lottonen-Raikaslehto L, Parviainen V, Huusko J, Pikkarainen S, Mendel M, Laham-Karam N, Kärjä V, Hedman M, Ylä-Herttuala S. 2015. Efficacy and safety of myocardial gene transfer of adenovirus, adeno-associated virus and lentivirus vectors in mouse heart. GENE THERAPY [epub ahead of print Dec 24, 2015]: -. 2015

Nguyen Su Duy, Javanainen Matti, Rissanen Sami, Zhao Hongxia, Huusko Jenni, Kivelä Annukka M, Ylä-Herttuala Seppo, Navab Mohamad, Fogelman Alan M, Vattulainen Ilpo, Kovanen Petri T, Öörni Katariina. 2015. Apolipoprotein A-I mimetic peptide 4F blocks sphingomyelinase-induced LDL aggregation. JOURNAL OF LIPID RESEARCH 56: 1206-1221. 2015

Husso Tiia, Turunen Mikko P, Ylä-Herttuala Seppo. 2015. Regulation of VEGF-A Expression in Endothelial Cells by Transcriptional Gene Activation or Transcriptional Gene Silencing: Analysis of Genome Wide Transcriptional Response. Gene Technology 4 2: 122. 2015

Aavik Einari, Lumivuori Henri, Leppänen Olli, Wirth Thomas, Häkkinen Sanna-Kaisa, Bräsen Jan-Hinrich, Beschorner Ulrich, Zeller Thomas, Braspenning Maarten, van Criekinge Wim, Mäkinen Kimmo, Ylä-Herttuala Seppo. 2015. Epigeneettiset muutokset ja mikro-RNA-klusterin aktivoituminen ateroskleroosiplakeissa. DUODECIM 131 4: 355. 2015

Merentie M, Lipponen JA, Hedman M, Hedman A, Hartikainen J, Huusko J, Lottonen-Raikaslehto L, Parviainen V, Laidinen S, Karjalainen PA, Ylä-Herttuala S. 2015. Mouse ECG findings in aging, with conduction system affecting drugs and in cardiac pathologies: Development and validation of ECG analysis algorithm in mice. PSYCHOLOGICAL REPORTS 3: e12639. 2015

Babu Mohan, Durga Devi Thota, Mäkinen Petri, Kaikkonen Minna, Lesch Hanna P, Junttila Sini, Laiho Asta, Ghimire Bishwa, Gyenesei Attila, Ylä-Herttuala Seppo. 2015. Differential Promoter Methylation of Macrophage Genes Is Associated With Impaired Vascular Growth in Ischemic Muscles of Hyperlipidemic and Type 2 Diabetic Mice: Genome-Wide Promoter Methylation Study. CIRCULATION RESEARCH [ONLINE: HTTP://CIRCRES.AHAJOURNALS.ORG/] 117: 289-299. 2015

Frederickson Robert, Ylä-Herttuala Seppo. 2015. Molecular Therapy Special Issue on Gene Editing Technologies and Applications. MOLECULAR THERAPY 23 8: 1279. 2015

Heinonen Suvi E, Guillem Genové, Bengtsson Eva, Hübschle Thomas, Åkesson Lina, Hiss Katrin, Benardeau Agnes, Ylä-Herttuala Seppo, Jönsson-Rylander Ann-Cathrine, Gomez Maria F. 2015. Animal Models of Diabetic Macrovascular Complications: Key Players in the Development of New Therapeutic Approaches. Journal of Diabetes Research 2015: 14 p. 2015

Airenne Kari J, Ylä-Herttuala Seppo. 2015. Baculovirus: A High-Capacity Vector for Versatile Gene Transfer: Nancy Smyth Templeton, Gene and Cell Therapy : Therapeutic Mechanisms and Strategies. Fourth Edition. 201-236. 2015

Kivelä Annukka M, Huusko Jenni, Ylä-Herttuala Seppo. 2015. Prospect and progress of gene therapy in treating atherosclerosis. EXPERT OPINION ON BIOLOGICAL THERAPY 15 12: 1699-1712. 2015

Laakkonen Johanna P., Ylä-Herttuala Seppo. 2015. Recent Advancements in Cardiovascular Gene Therapy and Vascular Biology. HUMAN GENE THERAPY 26 8: 518-524. 2015

Laham-Karam Nihay, Lalli Marianne, Leinonen Nastasia, Ylä-Herttuala Seppo. 2015. Differential Regulation of Vascular Endothelial Growth Factors by Promoter-targeted shRNAs. Molecular Therapy - Nucleic Acids 4: e243. 2015

Lesch Hanna P, Heikkilä Kati M, Lipponen Eevi M, Valonen Piia, Müller Achim, Räsänen Eva, Tuunanen Tarja, Hassinen Minna M, Parker Nigel, Karhinen Minna, Shaw Robert, Ylä-Herttuala Seppo. 2015. Process Development of Adenoviral Vector Production in Fixed Bed Bioreactor: From Bench to Commercial Scale. HUMAN GENE THERAPY 26 8: 560-571. 2015

Madonna Rosalinda, Petrov Lyobomir, Teberino Maria Anna, Manzoli Lamberto, Karam Jean-Pierre, Renna Francesca Vera, Ferdinandy Peter, Montero-Menei Claudia N, Ylä-Herttuala Seppo, De Caterina Raffaele. 2015. Transplantation of adipose tissue mesenchymal cells conjugated with VEGF-releasing microcarriers promotes repair in murine myocardial infarction. CARDIOVASCULAR RESEARCH 108 1: 39-49. 2015

Makkonen Kaisa-Emilia, Airenne Kari, Ylä-Herttuala Seppo. 2015. Baculovirus-mediated Gene Delivery and RNAi Applications. Viruses 7 4: 2099-2125. 2015

Kolari Ida-Liisa, Laitinen Pia, Turunen Mikko P, Ylä-Herttuala Seppo. 2015. Novel Nuclear Biology of Small Non-Coding RNAs. Gene Technology 4: 120. 2015

Turunen Tytteli AK, Laakkonen Johanna P, Alasaarela Laura, Airenne Kari J, Ylä-Herttuala Seppo. 2014. Sleeping Beauty-baculovirus hybrid vectors for long-term gene expression in the eye. JOURNAL OF GENE MEDICINE 16 1-2: 40-53. 2014

Tervala TV, Grönroos TJ, Hartiala P, Nuutila P, Suominen EA, Karra H, Kivinen K, Ylä-Herttuala S, Saarikko AM. 2014. Analysis of fat graft metabolic adaptation and vascularization using positron emission tomography-computed tomographic imaging. PLASTIC AND RECONSTRUCTIVE SURGERY 133 2: 291-299. 2014

Turkki Vesa, Schenkwein Diana, Timonen Oskari, Husso Tiia, Lesch Hanna P, Ylä-Herttuala Seppo. 2014. Lentiviral protein transduction with genome-modifying HIV-1 integrase-I-PpoI fusion proteins: studies on specificity and cytotoxicity. BioMed research international 2014;2014:379340.: Article ID 379340. 2014

Turunen Mikko P, Husso Tiia, Musthafa Haja, Laidinen Svetlana, Dragneva Galina, Laham-Karam Nihay, Honkanen Sanna, Paakinaho Anne, Laakkonen Johanna P, Gao Erhe, Vihinen-Ranta Maija, Liimatainen Timo, Ylä-Herttuala Seppo. 2014. Epigenetic upregulation of endogenous VEGF-A reduces myocardial infarct size in mice. PLOS ONE [ONLINE] 2014 Feb 26;9(2):e89979: e89979. 2014

Wirth Thomas, Ylä-Herttuala Seppo. 2014. Gene transfer vectors (DNA vehicles) and their incorporation into biomaterials for bone repair. In: Dubruel P, Vlierberghe SV (eds.) (ed.) Biomaterials for Bone Regeneration: Novel Techniques and Applications: Novel Techniques and Applications. ELSEVIER. s. 374-405. 2014

Uotila Sauli, Silvola Johanna MU, Saukko Pekka, Nuutila Pirjo, Heinonen Suvi E, Ylä-Herttuala Seppo, Roivainen Anne, Knuuti Juhani, Saraste Antti. 2014. [F-18]Fluorodeoxyglucose Uptake in Atherosclerotic Plaques Is Associated With Reduced Coronary Flow Reserve in Mice. JOURNAL OF ULTRASOUND IN MEDICINE 33 11: 1941-1948. 2014

Vuorio Taina, Nurmi Harri, Moulton Karen, Kurkipuro Jere, Robciuc Marius R, Öhman Miina, Heinonen Suvi E, Samaranayake Haritha, Heikura Tommi, Alitalo Kari, Ylä-Herttuala Seppo. 2014. Lymphatic vessel insufficiency in hypercholesterolemic mice alters lipoprotein levels and promotes atherogenesis. ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY 2014 Jun;34(6): 1162-70. 2014

Wirth Thomas, Ylä-Herttuala Seppo. 2014. Gene Therapy Used in Cancer Treatment. Biomedicines 2014, 2(2): 149-162. 2014

Ylä-Herttuala Seppo, Kaikkonen Minna. 2014. Does mass balance between sense and antisense transcripts fine-tune the outcome of gene expression?. EMBO REPORTS 2014 Feb;15(2): 125-126. 2014

Sallinen H, Heikura T, Koponen J, Kosma VM, Heinonen S, Ylä-Herttuala S, Anttila M. 2014. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC CANCER [ONLINE: HTTP://WWW.BIOMEDCENTRAL.COM/BMCCANCER/] 14 1: 1-10. 2014

Samaranayake Haritha D, Pikkarainen Jere T, Wirth Thomas, Stedt Hanna, Lesch Hanna P, Dragneva Galina, Vuorio Taina, Määttä Ann-Mari, Airenne Kari, Ylä-Herttuala Seppo. 2014. Soluble Vascular Endothelial Growth Factor Receptor-1 Improves Therapeutic Efficacy of Suicide Gene Therapy in an Angiogenesis-Independent Manner. HUMAN GENE THERAPY 25 11: 942-954. 2014

Aavik E, Lumivuori H, Leppänen O, Wirth T, Häkkinen SK, Bräsen JH, Beschorner U, Zeller T, Braspenning M, van Criekinge W, Mäkinen K, Ylä-Herttuala S. 2014. Global DNA methylation analysis of human atherosclerotic plaques reveals extensive genomic hypomethylation and reactivation at imprinted locus 14q32 involving induction of a miRNA cluster. EUROPEAN HEART JOURNAL 2014 Nov 16. pii: ehu437.: - -. 2014

Ruotsalainen JJ, Kaikkonen MU, Niittykoski M, Martikainen MW, Lemay CG, Cox J, De Silva NS, Kus A, Falls TJ, Diallo JS, Le Boeuf F, Bell JC, Ylä-Herttuala S, Hinkkanen AE, Vähä-Koskela MJ. 2014. Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model. GENE THERAPY 2014 Sep 18. [Epub ahead of print]: --. 2014

Husso Tiia, Ylä-Herttuala Seppo, Turunen Mikko P. 2014. A New Gene Therapy Approach for Cardiovascular Disease by Non-coding RNAs Acting in the Nucleus. Molecular Therapy - Nucleic Acids (2014) 3, e197: --. 2014

Ronkainen Veli-Pekka, Tuomainen Tomi, Huusko Jenni, Laidinen Svetlana, Malinen Marjo, Palvimo Jorma J, Ylä-Herttuala Seppo, Vuolteenaho Olli, Tavi Pasi. 2014. Hypoxia-inducible factor 1-induced G protein-coupled receptor 35 expression is an early marker of progressive cardiac remodelling. CARDIOVASCULAR RESEARCH 2014 Jan 1;101(1): 69-77. 2014

Dijkstra MH, Pirinen E, Huusko J, Kivelä R, Schenkwein D, Alitalo K, Ylä-Herttuala S. 2014. Lack of cardiac and high-fat diet induced metabolic phenotypes in two independent strains of Vegf-b knockout mice. Scientific Reports 4, Article number:6238: --. 2014

Dimmeler Stefanie, Ylä-Herttuala Seppo. 2014. 14q32 miRNA Cluster Takes Center Stage in Neovascularization. CIRCULATION RESEARCH 115 8: 680-682. 2014

Halonen Paavo J, Nurro Jussi, Kuivanen Antti, Ylä-Herttuala Seppo. 2014. Current gene therapy trials for vascular diseases. EXPERT OPINION ON BIOLOGICAL THERAPY 2014 Mar;14(3): 327-336. 2014

Gynther Mikko, Kääriäinen Tiina M, Hakkarainen Jenni J, Jalkanen Aaro J, Petsalo Aleksanteri, Lehtonen Marko, Peura Lauri, Kurkipuro Jere, Samaranayake Haritha, Yla-Herttuala Seppo, Rautio Jarkko, Forsberg Markus M. 2014. Brain Pharmacokinetics of Ganciclovir in Rats with Orthotopic BT4C Glioma. DRUG METABOLISM AND DISPOSITION 2015; 43: 140-146. 2014

Kaikkonen MU, Niskanen H, Romanoski CE, Kansanen E, Kivelä AM, Laitalainen J, Heinz S, Benner C, Glass CK, Ylä-Herttuala S. 2014. Control of VEGF-A transcriptional programs by pausing and genomic compartmentalization. NUCLEIC ACIDS RESEARCH 42 20: 12570-84. 2014

Kiviniemi Aida, Gardberg Maria, Autio Anu, Li Xiang-Guo, Heuser Vanina D, Liljenbäck Heidi, Käkelä Meeri, Sipilä Henri, Kurkipuro Jere, Ylä-Herttuala Seppo, Knuuti Juhani, Minn Heikki, Roivainen Anne. 2014. Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies. ACTA ONCOLOGICA 53 8: 1125-34. 2014

Korpisalo P, Hytönen JP, Laitinen JT, Närväinen J, Rissanen TT, Gröhn OH, Ylä-Herttuala S. 2014. Ultrasound imaging with bolus delivered contrast agent for the detection of angiogenesis and blood flow irregularities. AMERICAN JOURNAL OF PHYSIOLOGY. HEART AND CIRCULATORY PHYSIOLOGY 307 8: H1226-H1232. 2014

Makkonen KE, Turkki P, Laakkonen JP, Ylä-Herttuala S, Marjomäki V, Airenne KJ. 2014. Reply to Heparan Sulfate in Baculovirus Binding and Entry of Mammalian Cells. JOURNAL OF VIROLOGY 88 8: 4609-1460. 2014

Niemi Henna, Honkonen Krista, Korpisalo Petra, Huusko Jenni, Kansanen Emilia, Merentie Mari, Rissanen Tuomas T, André Helder, Pereira Teresa, Poellinger Lorenz, Alitalo Kari, Ylä-Herttuala Seppo. 2014. HIF-1 alpha and HIF-2 alpha induce angiogenesis and improve muscle energy recovery. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 44 10: 989-999. 2014

Turkki P, Makkonen KE, Huttunen M, Laakkonen JP, Ylä-Herttuala S, Airenne KJ, Marjomäki V. 2013. Cell susceptibility to baculovirus transduction and echovirus infection is modified by PKC phosphorylation and vimentin organization. JOURNAL OF VIROLOGY 2013 Jul 3. [Epub ahead of print]: [Epub ahead of print]. 2013

Rissanen TT, Nurro J, Halonen PJ, Tarkia M, Saraste A, Rannankari M, Honkonen K, Pietilä M, Leppänen O, Kuivanen A, Knuuti J, Ylä-Herttuala S. 2013. The bottleneck stent model for chronic myocardial ischemia and heart failure in pigs. AMERICAN JOURNAL OF PHYSIOLOGY. HEART AND CIRCULATORY PHYSIOLOGY 305 9: H1297-308. 2013

Ruotsalainen AK, Inkala M, Partanen ME, Lappalainen JP, Kansanen E, Mäkinen PI, Heinonen SE, Laitinen HM, Heikkilä J, Vatanen T, Hörkkö S, Yamamoto M, Ylä-Herttuala S, Jauhiainen M, Levonen AL. 2013. The absence of macrophage Nrf2 promotes early atherogenesis. CARDIOVASCULAR RESEARCH 2013 Apr 1;98(1): 107-15. 2013

Stedt H, Samaranayake H, Pikkarainen J, Määttä AM, Alasaarela L, Airenne K, Ylä-Herttuala S. 2013. Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide. GENE THERAPY 20: --. 2013

Tuppurainen L, Sallinen H, Hakkarainen H, Liimatainen T, Hassan M, Ylä-Herttuala E, Anttila M, Hämäläinen K, Veli-Matti Kosma, Heinonen S, Alitalo K, Ylä-Herttuala S. 2013. Functional MRI Measurements to Predict Early Adenoviral Gene Therapy Response in Ovarian Cancer Mouse Model. Journal of Genetic Syndromes & Gene Therapy 4 8: x-x. 2013

Tuppurainen L, Sallinen H, Kokki E, Koponen J, Anttila M, Pulkkinen K, Heikura T, Toivanen P, Hämäläinen K, Kosma VM, Heinonen S, Alitalo K, Ylä-Herttuala S. 2013. Preclinical Safety, Toxicology, and Biodistribution Study of Adenoviral Gene Therapy with sVEGFR-2 and sVEGFR-3 Combined with Chemotherapy for Ovarian Cancer. Human Gene Therapy Clinical Development 24 1: 29-37. 2013

Ylä-Herttuala S. 2013. Geeniterapialääkkeet tekevät tuloaan. DUODECIM 2013;129(8): 788-9. 2013

Turunen MP, Aavik E, Ylä-Herttuala S. 2013. Epigenetic regulation in vascular cells. CURRENT OPINION IN LIPIDOLOGY 2013 Jul 18. [Epub ahead of print] 24: x-x. 2013

Westphal M, Ylä-Herttuala S, Martin J, Warnke P, Menei P, Eckland D, Kinley J, Kay R, Ram Z; ASPECT Study Group. 2013. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. LANCET ONCOLOGY 14 9: 823-33. 2013

Wirth T, Parker N, Ylä-Herttuala S. 2013. History of gene therapy. GENE 2013 Aug 10;525(2): 162-9. 2013

Ylä-Herttuala S, Aavik E. 2013. Modified RNA kick-starts cardiac repair. NATURE BIOTECHNOLOGY 2013 Oct;31(10):: 891-2. 2013

Ylä-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J, Hoefer I, Jauhiainen S, Jukema JW, Krams R, Kwak BR, Marx N, Naruszewicz M, Newby A, Pasterkamp G, Serruys PW, Waltenberger J, Weber C, Tokgözoglu L; ESC Working Group of Atherosclerosis and Vascular Biology. 2013. Stabilization of atherosclerotic plaques: an update. EUROPEAN HEART JOURNAL 34 42: 3251-8. 2013

Ylä-Herttuala S. 2013. Cardiovascular gene therapy with vascular endothelial growth factors. GENE 2013 Aug 10;525(2): 217-9. 2013

Nieminen T, Toivanen PI, Rintanen N, Heikura T, Jauhiainen S, Airenne KJ, Alitalo K, Marjomäki V, Ylä-Herttuala S. 2013. The impact of the receptor binding profiles of the vascular endothelial growth factors on their angiogenic features. BIOCHIMICA ET BIOPHYSICA ACTA 1840 1: 454-463. 2013

Pomeshchik Y, Kidin I, Savchenko E, Rolova T, Yamamoto M, Levonen AL, Ylä-Herttuala S, Malm T, Kanninen K, Koistinaho J. 2013. Does Nrf2 Gene Transfer Facilitate Recovery After Contusion Spinal Cord Injury?. ANTIOXIDANTS AND REDOX SIGNALING 2013 Aug 20. [Epub ahead of print]: x-x. 2013

Paterson I, Wells GA, Ezekowitz JA, White JA, Friedrich MG, Mielniczuk LM, O'Meara E, Chow B, DeKemp RA, Klein R, Dennie C, Dick A, Coyle D, Dwivedi G, Rajda M, Wright GA, Laine M, Hanninen H, Larose E, Connelly KA, Leong-Poi H, Howarth AG, Davies RA, Duchesne L, Yla-Herttuala S, Saraste A, Farand P, Garrard L, Tardif JC, Arnold M, Knuuti J, Beanlands R, Chan KL. 2013. Routine versus selective cardiac magnetic resonance in non-ischemic heart failure - OUTSMART-HF: study protocol for a randomized controlled trial (IMAGE-HF (heart failure) project 1-B). TRIALS [ONLINE] 2013 Oct 12;14:332.: --. 2013

Mäkinen PI, Ylä-Herttuala S. 2013. Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis. CURRENT OPINION IN LIPIDOLOGY 2013 Apr;24(2): 116-22. 2013

Gomes RS, das Neves RP, Cochlin L, Lima A, Carvalho R, Korpisalo P, Dragneva G, Turunen M, Liimatainen T, Clarke K, Ylä-Herttuala S, Carr C, Ferreira L. 2013. Efficient pro-survival/angiogenic miRNA delivery by an MRI-detectable nanomaterial. ACS NANO 2013 Apr 23;7(4): 3362-72. 2013

Abete P, Adlbrecht C, Assimakopoulos S, Cote N, Dullaart R, Evsyukova H, Fang T, Goswami N, Hinghofer-Szalkay H, Ho Y, Hoebaus C, lsmann M, Indridason O, Kholova I, Lin Y, Maniscalco M, Mathieu P, Mizukami H, Ndrepepa G, Roessler A, Sanchez-Ramon S, Santamaria F, Schernthaner G, Scopa C, Sharp K, Skuladottir G, Steichen O, Stenvinkel P, Tejera-Alhambra M, Testa G, Visseren F, Westerink J, Witasp A. 2013. Research update for articles published in EJCI in 2011. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION Volume 43, Issue 10: 1097-111. 2013

Anisimov A, Tvorogov D, Alitalo A, Leppänen VM, An Y, Han EC, Orsenigo F, Gaál EI, Holopainen T, Koh YJ, Tammela T, Korpisalo P, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Dejana E, Koh GY, Choi C, Saharinen P, Alitalo K. 2013. Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. CIRCULATION 2013 Jan 29;127(4): 424-34. 2013

Avramoglu RK, Laplante M-A, Quang KL, Deshaies Y, Despres J-P, Larose E, Mathieu P, Poirier P, Perusse L, Vohl M-C, Sweeney G, Ylä-Herttuala S, Laakso M, Uusitupa M, Marette A. 2013. The Genetic and Metabolic Determinants of Cardiovascular Complications in Type 2 Diabetes: Recent Insights from Animal Models and Clinical Investigations. Canadian Journal of Diabetes 37 5: 351-358. 2013

Chow BJ, Green RE, Coyle D, Laine M, Hanninen H, Leskinen H, Rajda M, Larose E, Hartikainen J, Hedman M, Mielniczuk L, O Meara E, Dekemp RA, Klein R, Paterson I, White JA, Yla-Herttuala S, Leber A, Tandon V, Lee T, Al-Hesayen A, Hessian R, Dowsley T, Kass M, Kelly C, Garrard L, Tardif JC, Knuuti J, Beanlands RS, Wells GA.. 2013. Computed tomographic coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE HF Project 1-C). TRIALS [ONLINE] 14: 443. 2013

Dragneva G, Korpisalo P, Ylä-Herttuala S. 2013. Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success. Disease models & mechanisms 2013 Mar;6(2): 312-22. 2013

Frösen J, Tulamo R, Heikura T, Sammalkorpi S, Niemelä M, Hernesniemi J, Levonen AL, Hörkkö S, Ylä-Herttuala S. 2013. Lipid accumulation, lipid oxidation, and low plasma levels of acquired antibodies against oxidized lipids associate with degeneration and rupture of the intracranial aneurysm wall. Acta neuropathologica communications 1: 71. 2013

Airenne KJ, Hu YC, Kost TA, Smith RH, Kotin RM, Ono C, Matsuura Y, Wang S, Ylä-Herttuala S. 2013. Baculovirus: an insect-derived vector for diverse gene transfer applications. MOLECULAR THERAPY 21 4: 739-49. 2013

Heinonen SE, Kivelä AM, Huusko J, Dijkstra MH, Gurzeler E, Mäkinen PI, Leppänen P, Olkkonen VM, Eriksson U, Jauhiainen M, Ylä-Herttuala S.. 2013. The effects of VEGF-A on atherosclerosis, lipoprotein profile, and lipoprotein lipase in hyperlipidaemic mouse models. CARDIOVASCULAR RESEARCH 99 4: 716-23. 2013

Ivanov KI, Agalarov Y, Valmu L, Samuilova O, Liebl J, Houhou N, Maby-El Hajjami H, Norrmén C, Jaquet M, Miura N, Zangger N, Ylä-Herttuala S, Delorenzi M, Petrova TV. 2013. Phosphorylation regulates FOXC2-mediated transcription in lymphatic endothelial cells. MOLECULAR AND CELLULAR BIOLOGY 2013 Oct;33(19): 3749-6. 2013

Jazwa A, Tomczyk M, Taha HM, Hytonen E, Stoszko M, Zentilin L, Giacca M, Yla-Herttuala S, Emanueli C, Jozkowicz A, Dulak. 2013. Arteriogenic therapy based on simultaneous delivery of VEGF-A and FGF4 genes improves the recovery from acute limb ischemia. Vascular cell 2013 Jul 1;5(1):13.: - -. 2013

Kinnunen K, Heinonen SE, Kalesnykas G, Laidinen S, Uusitalo-Järvinen H, Uusitalo H, Ylä-Herttuala S. 2013. LDLR(-/-)ApoB(100/100) mice with insulin-like growth factor II overexpression reveal a novel form of retinopathy with photoreceptor atrophy and altered morphology of the retina. MOLECULAR VISION [ONLINE: HTTP://WWW.MOLVIS.ORG/MOLVIS/] 19: 1723-1733. 2013

Laplante MA, Charbonneau A, Avramoglu RK, Pelletier P, Fang X, Bachelard H, Ylä-Herttuala S, Laakso M, Després JP, Deshaies Y, Sweeney G, Mathieu P, Marette A. 2013. Distinct metabolic and vascular effects of dietary triglycerides and cholesterol in atherosclerotic and diabetic mouse models. AMERICAN JOURNAL OF PHYSIOLOGY. ENDOCRINOLOGY AND METABOLISM [PRINTED AND ONLINE: HTTP://AJPENDO.PHYSIOLOGY.ORG/] vol. 305 no. 5: E573-E584. 2013

Makkonen KE, Turkki P, Laakkonen JP, Ylä-Herttuala S, Marjomäki V, Airenne KJ. 2013. 6-O sulfated and N-sulfated Syndecan-1 promotes baculovirus binding and entry into mammalian cells. JOURNAL OF VIROLOGY 2013 Oct;87 20: 11148-59. 2013

Huhtala Tuulia, Kaikkonen Minna U, Lesch Hanna P, Viitala Sari, Ylä-Herttuala Seppo, Närvänen Ale. 2013. Biodistribution and antitumor effect of Cetuximab-targeted lentivirus. NUCLEAR MEDICINE AND BIOLOGY 2014:41: 77-83. 2013

Vuorio, T., Jauhiainen, S., Ylä-Herttuala, S. 2012. Pro- and anti-angiogenic therapy and atherosclerosis with special emphasis on vascular endothelial growth factors. EXPERT OPINION ON BIOLOGICAL THERAPY 2012 Jan;12(1): 79-92. 2012

Soininen Suvi K, Lehtolainen-Dalkilic Pauliina, Karppinen Tanja, Puustinen Tiina, Dragneva Galina, Kaikkonen Minna U, Jauhiainen Marjo, Allart Brigitte, Selwood David L, Wirth Thomas, Lesch Hanna P, Määttä Ann-Marie, Mönkkönen Jukka, Ylä-Herttuala Seppo, Ruponen Marika. 2012. Targeted delivery via avidin fusion protein: Intracellular fate of biotinylated doxorubicin derivative and cellular uptake kinetics and biodistribution of biotinylated liposomes. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 47: 848-856. 2012

Sopo M, Anttila M, Sallinen H, Tuppurainen L, Laurema A, Laidinen S, Hamalainen K, Tuunanen P, Koponen JK, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S. 2012. Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma. INTERNATIONAL JOURNAL OF CANCER 131 10: 234-2401. 2012

Stedt Hanna, Alasaarela Laura, Samaranayake Haritha, Pikkarainen Jere, Määttä Ann-Marie, Kholová Ivana, Parker Aaron S, Ylä-Herttuala Seppo. 2012. Specific Inhibition of SRC Kinase Impairs Malignant Glioma Growth In Vitro and In Vivo. Molecular Therapy - Nucleic Acids 2012 May; 1(5): e19: - -. 2012

Toivonen R, Koskenvuo J, Merentie M, Söderström M, Ylä-Herttuala S, Savontaus M. 2012. Intracardiac injection of a capsid-modified Ad5/35 results in decreased heart toxicity when compared to standard Ad5. Virology journal 2012 Nov 29;9(1):296. [Epub ahead of print]: - -. 2012

Viita H, Pacholska A, Ahmad F, Tietäväinen J, Naarala J, Hyvärinen A, Wirth T, Ylä-Herttuala S. 2012. 15-lipoxygenase-1 induces lipid peroxidation and apoptosis, and improves survival in rat malignant glioma IN VIVO (ATHENS) 2012 Jan-Feb;26(1): 1-8. 2012

Ylä-Herttuala Seppo. 2012. Cardiovascular gene therapy trials: Cohen-Haguenauer O, The clinibook - clinical gene transfer. 475-478. 2012

Wirth T, Ahmad F, Pacholska A, Samaranayake H, Ylä-Herttuala S. 2012. The Syngeneic BT4C Rat Malignant Glioma is a Valuable Model to Study Myelomonocytic Cells in Tumors. Cancer Growth and Metastasis 2012:5: 19-25. 2012

Wirth T, Pikkarainen JT, Samaranayake HD, Lehtolainen-Dalkilic P, Lesch HP, Airenne KJ, Marjomäki V, Ylä-Herttuala S. 2012. Efficient gene therapy based targeting system for the treatment of inoperable tumors. JOURNAL OF GENE MEDICINE 2012 Apr;14(4): 221-30. 2012

Ylä-Herttuala S. 2012. The need for increased clarity and transparency in the regulatory pathway for gene medicines in the European Union. MOLECULAR THERAPY 2012 Mar;20(3): 471-2. 2012

Ylä-Herttuala Seppo. 2012. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. MOLECULAR THERAPY 2012 Oct;20(10): 1831-2. 2012

Ylä-Herttuala Seppo. 2012. General principles and approaches of gene therapy. In: Morishita R, Nakagami H (ed.) , Gene Therapy: Technologies and Applications. Future Science Group (FSG) E-Book Series.. ss. --. 2012

Ylä-Herttuala Seppo. 2012. Treatment of brain tumors with adenoviruses: preclinical development: Cohen-Haguenauer O, The CliniBook: Clinical gene transfer. 242-244. 2012

Saraste A, Laitinen I, Weidl E, Wildgruber M, Weber AW, Nekolla SG, Hölzlwimmer G, Esposito I, Walch A, Leppänen P, Lisinen I, Luppa PB, Ylä-Herttuala S, Wester HJ, Knuuti J, Schwaiger M. 2012. Diet intervention reduces uptake of αvβ3 integrin-targeted PET tracer 18F-Galacto-RGD in mouse atherosclerotic plaques. JOURNAL OF NUCLEAR CARDIOLOGY 2012 Aug;19(4): 775-84. 2012

Schenkwein D, Turkki V, Ahlroth MK, Timonen O, Airenne KJ, Ylä-Herttuala S. 2012. rDNA-directed integration by an HIV-1 integrase--I-PpoI fusion protein. NUCLEIC ACIDS RESEARCH 2012 Dec 28. [Epub ahead of print]: --. 2012

Huusko J, Lottonen L, Merentie M, Gurzeler E, Anisimov A, Miyanohara A, Alitalo K, Tavi P, Ylä-Herttuala S. 2012. AAV9-mediated VEGF-B Gene Transfer Improves Systolic Function in Progressive Left Ventricular Hypertrophy. MOLECULAR THERAPY 20 (2012): 2212 - 2221. 2012

Partanen TA, Vuola P, Jauhiainen S, Lohi J, Salminen P, Pitkäranta A, Häkkinen SK, Honkonen K, Alitalo K, Ylä-Herttuala S. 2012. Neuropilin-2 and vascular endothelial growth factor receptor-3 are up-regulated in human vascular malformations. Angiogenesis 2012 Sep 9. [Epub ahead of print]: --. 2012

Aavik Einari, Turunen Mikko P, Ylä-Herttuala Seppo. 2012. Epigenetics and Atherosclerosis. In: Minarovits Janos, Niller Hans Helmut (ed.) Patho-Epigenetics of Disease. Springer science+business media. s. 397-418. 2012

Heikura T, Nieminen T, Roschier MM, Karvinen H, Kaikkonen MU, Mähönen AJ, Lesch HP, Rissanen TT, Laitinen OH, Airenne KJ, Ylä-Herttuala S.. 2012. Baculovirus-mediated vascular endothelial growth factor-D∆N∆C gene transfer induces angiogenesis in rabbit skeletal muscle. JOURNAL OF GENE MEDICINE 14 1: 35-43. 2012

Holopainen T, Saharinen P, D'Amico G, Lampinen A, Eklund L, Sormunen R, Anisimov A, Zarkada G, Lohela M, Heloterä H, Tammela T, Benjamin LE, Ylä-Herttuala S, Leow CC, Koh GY, Alitalo K. 2012. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. JOURNAL OF THE NATIONAL CANCER INSTITUTE 2012 Mar 21;104(6): 461-75. 2012

Honkonen KM, Visuri MT, Tervala TV, Halonen PJ, Koivisto M, Lähteenvuo MT, Alitalo KK, Ylä-Herttuala S, Saaristo AM. 2012. Lymph Node Transfer and Perinodal Lymphatic Growth Factor Treatment for Lymphedema. Annals of surgery 2012 Sep 25. [Epub ahead of print]: - -. 2012

Kinnunen, K; Ylä-Herttuala, S. 2012. Gene therapy in age related and hereditary macular disorders FRONTIERS IN BIOSCIENCE 4: 2546-2557. 2012

Kivelä A, Hartikainen J, Ylä-Herttuala S. 2012. Dotted collar placed around carotid artery induces asymmetric neointimal lesion formation in rabbits without intravascular manipulations. BMC CARDIOVASCULAR DISORDERS [ONLINE: HTTP://WWW.BIOMEDCENTRAL.COM/1471-2261/] 2012 Oct 17;12:91.: --. 2012

Kivelä AM, Dijkstra MH, Heinonen SE, Gurzeler E, Jauhiainen S, Levonen AL, Ylä-Herttuala S. 2012. Regulation of endothelial lipase and systemic HDL cholesterol levels by SREBPs and VEGF-A. ATHEROSCLEROSIS 2012 Oct 9. [Epub ahead of print] pii: S0021-9150(12)00657-0.: --. 2012

Kotimaa AA, Zainana AM, Pulkkinen E, Huusko J, Heinonen SE, Kholová I, Stedt H, Lesch HP, Ylä-Herttuala S. 2012. Endothelium-specific overexpression of human vascular endothelial growth factor-D in mice leads to increased tumor frequency and a reduced lifespan. JOURNAL OF GENE MEDICINE 2012 Mar;14(3): 182-90. 2012

Krebs R, Tikkanen JM, Ropponen JO, Jeltsch M, Jokinen JJ, Ylä-Herttuala S, Nykänen AI, Lemström KB. 2012. Critical role of VEGF-C/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis. AMERICAN JOURNAL OF PATHOLOGY 2012 Nov;181(5): 1607-20. 2012

Kuusisto J, Kärjä V, Sipola P, Kholová I, Peuhkurinen K, Jääskeläinen P, Naukkarinen A, Ylä-Herttuala S, Punnonen K, Laakso M. 2012. Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. HEART 98 13: 1007-1013. 2012

Leinonen HM, Ruotsalainen AK, Määttä AM, Laitinen HM, Kuosmanen SM, Kansanen E, Pikkarainen JT, Lappalainen JP, Samaranayake H, Lesch HP, Kaikkonen MU, Ylä-Herttuala S, Levonen AL. 2012. Oxidative stress-regulated lentiviral TK/GCV gene therapy for lung cancer treatment. CANCER RESEARCH 2012 Oct 9. [Epub ahead of print]: - -. 2012

Maldiney T, Kaikkonen MU, Seguin J, le Masne de Chermont Q, Bessodes M, Airenne KJ, Ylä-Herttuala S, Scherman D, Richard C. 2012. In vitro targeting of avidin-expressing glioma cells with biotinylated persistent luminescence nanoparticles. BIOCONJUGATE CHEMISTRY 2012 Mar 21;23(3): 472-8. 2012

Murugan S, Saarela U, Airenne K, Shan J, Skovorodkin I, Ylä-Herttuala S, Vainio SJ. 2012. Conditional expression of Lodavin, an avidin-tagged LDL receptor, for biotin-mediated applications in vivo. Genesis (New York, N.Y. : 2000) 2012 Sep;50(9): 693-9. 2012

Musthafa HS, Dragneva G, Lottonen L, Merentie M, Petrov L, Heikura T, Ylä-Herttuala E, Ylä-Herttuala S, Gröhn O, Liimatainen T. 2012. Longitudinal rotating frame relaxation time measurements in infarcted mouse myocardium in vivo. MAGNETIC RESONANCE IN MEDICINE 2012 Jun 26 [Epub ahead of print]: --. 2012

Pacholska A, Wirth T, Samaranayake H, Pikkarainen J, Ahmad F, Ylä-Herttuala S. 2012. Increased invasion of malignant gliomas after 15-LO-1 and HSV-tk/ganciclovir combination gene therapy. CANCER GENE THERAPY 2012 Dec;19(12) Epub 2012 Oct 19: 870-4. 2012

Silvola JM, Laitinen I, Sipilä HJ, Laine VJ, Leppänen P, Ylä-Herttuala S, Knuuti J, Roivainen A. 2011. Uptake of 68gallium in atherosclerotic plaques in LDLR-/-ApoB100/100 mice EJNMMI research 2011, 1:14: --. 2011

Silvola J, Saraste A, Laitinen I, Nina Savisto N, Laine JO, Heinonen SE, Ylä-Herttuala S, Saukko P,Nuutila P, Roivainen A, Knuuti J. 2011. Effects of Age, Diet, and Type 2 Diabetes on the Development and FDG Uptake of Atherosclerotic Plaques JACC: CARDIOVASCULAR IMAGING 2011; 4: 1294-1301. 2011

Serpi Raisa, Tolonen Anna-Maria, Huusko Jenni, Rysä Jaana, Tenhunen Olli, Ylä-Herttuala Seppo, Ruskoaho Heikki. 2011. Vascular endothelial growth factor-B gene transfer prevents angiotensin II-induced diastolic dysfunction via proliferation and capillary dilatation in rats. CARDIOVASCULAR RESEARCH 89: 204-213. 2011

Lähteenvuo Markku, Honkonen Krista, Tervala Tomi, Tammela Tuomas , Suominen Erkki, Lähteenvuo Johanna, Kholová Ivana, Alitalo Kari, Ylä-Herttuala Seppo, Saaristo Anne. 2011. Growth factor therapy and autologous lymph node transfer in lymphedema. CIRCULATION 123: 613-620. 2011

Sallinen H, Anttila M, Gröhn O, Koponen J, Hämäläinen K, Kholova I, Heikura T, Kosma VM, Heinonen S, Alitalo K, Ylä-Herttuala S. 2011. VEGFR-1 and -3 and angiopoietin receptor Tie2 targeted gene therapy prevents the growth of solid human ovarian cancer in mice compared to cotargeting Tie1 and Tie2. CANCER GENE THERAPY 18 2: 100-9. 2011

Pulkkinen KH, Ylä-Herttuala S, Levonen AL. 2011. Heme oxygenase 1 is induced by miR-155 via reduced BACH1 translation in endothelial cells FREE RADICAL BIOLOGY & MEDICINE 2011 Dec 1;51(11): 2124-31. 2011

Muona K, Mäkinen K, Hedman M, Manninen H, Ylä-Herttuala S. 2011. 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. GENE THERAPY 2011 Jul 21.: --. 2011

Tammela Tuomas, Saaristo Anne, Holopainen Tanja, Ylä-Herttuala Seppo, Andersson Leif C, Virolainen Susanna, Immonen Ilkka, Alitalo Kari. 2011. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis SCIENCE TRANSLATIONAL MEDICINE 3: "-". 2011

Silvola Johanna MU, Saraste Antti, Forsback Sarita, Laine V Jukka O, Saukko Pekka, Heinonen Suvi E, Ylä-Herttuala Seppo, Roivainen Anne, Knuuti Juhani. 2011. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY 31: 1011-1015. 2011

Ylä-Herttuala Seppo, Glass Christopher K. 2011. Review focus on epigenetics and the histone code in vascular biology CARDIOVASCULAR RESEARCH 90: 402-403. 2011

Tammela Tuomas, Zarkada Georgia, Nurmi Harri, Jakobsson Lars, Heinolainen Krista,Tvorogov Denis, Zheng Wei, Franco Caludio A, Murtomäki Aino, Aranda Evelyn, Miura Naoyuki ,Ylä-Herttuala Seppo, Fruttiger Marcus, Mäkinen Taija, Eichmann Anne, Pollard Jeffrey W, Gerhardt Holger, Alitalo Kari. 2011. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling NATURE CELL BIOLOGY 13: 1202-1213. 2011

Turunen Mikko P, Ylä-Herttuala Seppo. 2011. Epigenetic regulation of key vascular genes and growth factors. CARDIOVASCULAR RESEARCH 90: 441-446. 2011

Wirth T, Samaranayake H, Ylä-Herttuala S. 2011. Glioblastoma Multiforme: Use of Adenoviral Vectors: Hayat, MA, Tumors of the Central Nervous System, Volume 2. 335-347. 2011

Wirth T, Ylä-Herttuala S. 2011. Gene Therapy of Glioblastoma Multiforme - Clinical Experience on the Use of Adenoviral Vectors: Ana L. Abujamra, Brain Tumors - Current and Emerging Therapeutic Strategies. 403-422. 2011

Ylä-Herttuala S, Wirth T. 2011. Therapeutic delivery using gene-delivery methods Therapeutic Delivery April 2011, Vol. 2, No. 4: 423-426. 2011

Ylä-Herttuala Seppo, Bentzon Jacob Fog, Daemen Mat, Falk Erling, Garcia-Garcia Hector M, Herrmann Joerg, Hoefer Imo, Jukema J. Wouter, Krams Rob, Kwak Brenda R, Marx Nikolaus, Naruszewicz Marek, Newby Andrew, Pasterkamp Gerard, Serruys Patrick WJC, Waltenberger Johannes, Weber Christian, Tokgözoglu Lale. 2011. Stabilisation of atherosclerotic plaques THROMBOSIS AND HAEMOSTASIS 106: 1-19. 2011

Ylä-Herttuala Seppo. 2011. Gene therapy moves forward in 2010. MOLECULAR THERAPY 19: 219-220. 2011

Zheng W, Tammela T, Yamamoto M, Anisimov A, Holopainen T, Kaijalainen S, Karpanen T, Lehti K, Ylä-Herttuala S, Alitalo K. 2011. Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor BLOOD 2011 Jul 28;118(4): 1154-62. 2011

Lesch HP, Laitinen A, Peixoto C, Vicente T, Makkonen KE, Laitinen L, Pikkarainen JT, Samaranayake H, Alves PM, Carrondo MJ, Ylä-Herttuala S, Airenne KJ. 2011. Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors. GENE THERAPY 18: 531-538. 2011

Liimatainen T, Sierra A, Hanson T, Sorce DJ, Ylä-Herttuala S, Garwood M, Michaeli S, Gröhn O. 2011. Glioma cell density in a rat gene therapy model gauged by water relaxation rate along a fictitious magnetic field. Magn. Reson. Med. 67; 269-277, 2012 MAGNETIC RESONANCE IN MEDICINE 2012 Jan;67(1) Epub 2011 Jun 30: 269-277. 2011

Heikura T, Nieminen T, Roschier M, Karvinen H, Kaikkonen M, Mähönen A, Lesch H, Rissanen T, Laitinen O, Airenne K, Ylä-Herttuala S. 2011. Baculovirus-mediated VEGF-D(ΔNΔC) Gene Transfer Induces Angiogenesis In Rabbit Skeletal Muscle. JOURNAL OF GENE MEDICINE 2011 Dec 12: --. 2011

Lesch Hanna P, Makkonen Kaisa-Emilia, Laitinen Anna, Määttä Ann-Marie, Närvänen Outi, Airenne Kari J, Ylä-Herttuala Seppo. 2011. Requirements for baculoviruses for clinical gene therapy applications. JOURNAL OF INVERTEBRATE PATHOLOGY 107: S106-S112. 2011

Kaikkonen Minna U, Ylä-Herttuala Seppo, Airenne Kari J. 2011. How to avoid complement attack in baculovirus-mediated gene delivery JOURNAL OF INVERTEBRATE PATHOLOGY 107: S71-S79. 2011

Ahmad Farizan, Pacholska Agnieszka, Tuppurainen Venla, Ylä-Herttuala Seppo, Hyvärinen Anna. 2011. Resectable VX-2 rabbit brain tumor model for development of intraoperative local administration of drugs. ACTA NEUROCHIRURGICA (WIEN) 153: 1979-1981. 2011

Airenne Kari J, Makkonen Kaisa-Emilia, Mähönen Anssi J, Ylä-Herttuala Seppo. 2011. Baculoviruses mediate efficient gene expression in a wide range of vertebrate cells: Merten, O-W. ja Al-Rubeai, M., Viral Vectors for Gene Therapy. Methods and Protocols. Methods in Molecular Biology. 279-301. 2011

Bhardwaj S, Roy H, Babu M, Shibuya M, Yla-Herttuala S. 2011. Adventitial gene transfer of VEGFR-2 specific VEGF-E chimera induces MCP-1 expression in vascular smooth muscle cells and enhances neointimal formation. ATHEROSCLEROSIS 2011 Nov;219(1): 84-91. 2011

Heinonen Suvi E, Merentie Mari, Hedman Marja, Mäkinen Petri I, Loponen Elina, Kholová Ivana, Bosch Fatima, Laakso Markku, Ylä-Herttuala Seppo. 2011. Left ventricular dysfunction with reduced functional cardiac reserve in diabetic and non-diabetic LDL-receptor deficient apolipoprotein B100-only mice. CARDIOVASCULAR DIABETOLOGY [ONLINE: HTTP://WWW.CARDIAB.COM/] 10: 1-12. 2011

Husso T, Turunen M, Parker N, Ylä-Herttuala S. 2011. Epigenetherapy, a new concept. BioMolecular Concepts Volume 2, Issue 3: 127-134. 2011

Jauhiainen Suvi, Häkkinen Sanna-Kaisa, Toivanen Pyry I, Heinonen Suvi E, Jyrkkänen Henna-Kaisa, Kansanen Emilia, Leinonen Hanna, Levonen Anna-Liisa, Ylä-Herttuala Seppo. 2011. Vascular endothelial growth factor (VEGF)-D stimulates VEGF-A, stanniocalcin-1, and neuropilin-2 and has potent angiogenic effects. ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY 31: 1617-1624. 2011

Jyrkkänen HK, Kuosmanen S, Heinäniemi M, Laitinen H, Kansanen E, Mella-Aho E, Leinonen H, Ylä-Herttuala S, Levonen AL. 2011. Novel insights into the regulation of antioxidant-response-element-mediated gene expression by electrophiles: induction of the transcriptional repressor BACH1 by Nrf2 BIOCHEMICAL JOURNAL 2011 Dec 1;440(2): 167-74. 2011

Hedman, Marja; Hartikainen, Juha; Ylä-Herttuala, Seppo. 2011. Progress and prospects: hurdles to cardiovascular gene therapy clinical trials. GENE THERAPY 18 8: 743-749. 2011

Kalén Mattias, Heikura Tommi, Karvinen Henna, Nitzsche Anja, Weber Holger, Esser Norbert, Ylä-Herttuala Seppo, Hellström Mats. 2011. Gamma-secretase inhibitor treatment promotes VEGF-A-driven blood vessel growth and vascular leakage but disrupts neovascular perfusion. PLOS ONE [ONLINE] 6: e18709. 2011

Krebs R, Tikkanen J, Ropponen JO, Jeltsch M, Jokinen JJ, Yla-Herttuala S,Koskinen PK, Nykanen AI, Lemstrom KB. 2011. VEGF-C/VEGFR-3 Signaling Regulates Inflammatory Response in Development of Obliterative Airway Disease JOURNAL OF HEART AND LUNG TRANSPLANTATION 30: 118-118. 2011

Kansanen Emilia, Bonacci Gustavo, Schopfer Francisco J, Kuosmanen Suvi M, Tong Kit I, Leinonen Hanna, Woodcock Steven R, Yamamoto Masayuk, Carlberg Carsten, Ylä-Herttuala Seppo, Freeman Bruce A, Levonen Anna-Liisa. 2011. Electrophilic nitro-fatty acids activate NRF2 by a KEAP1 cysteine 151-independent mechanism. JOURNAL OF BIOLOGICAL CHEMISTRY 286: 14019-14027. 2011

Kurki Mitja I, Paananen Jussi, Storvik Markus, Ylä-Herttuala Seppo, Jääskeläinen Juha E, Fraunberg von und zu Mikael, Wong Garry, Pehkonen Petri. 2011. TAFFEL: Independent enrichment analysis of gene sets. BMC BIOINFORMATICS [ONLINE] 12: 171. 2011

Kurki MI, Häkkinen SK, Frösen J, Tulamo R, von und zu Fraunberg M, Wong G, Tromp G, Niemelä M, Hernesniemi J, Jääskeläinen JE, Ylä-Herttuala S. 2011. Upregulated signaling pathways in ruptured human saccular intracranial aneurysm wall: an emerging regulative role of Toll-like receptor signaling and nuclear factor-κB, hypoxia-inducible factor-1A, and ETS transcription factors NEUROSURGERY 68 6: 1667-1675. 2011

Leppänen Veli-Matti, Jeltsch Michael, Anisimov Andrey, Tvorogov Denis, Aho Kukka, Kalkkinen Nisse, Toivanen Pyry, Ylä-Herttuala Seppo, Ballmer-Hofer Kurt, Alitalo Kari. 2011. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. BLOOD 117: 1507-1515. 2011

Kinnunen K, Ylä-Herttuala S. 2011. Vascular endothelial growth factors in retinal and choroidal neovascular diseases. Annals of Medicine Posted online on February 1, 2011: --. 2011

Kholová Ivana, Dragneva Galina, Cermáková Petra, Laidinen Svetlana, Kaskenpää Nina, Hazes Thierry, Cermáková Eva, Steiner Ivo, Ylä-Herttuala Seppo. 2011. Lymphatic vasculature is increased in heart valves, ischaemic and inflamed hearts and in cholesterol-rich and calcified atherosclerotic lesions. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 41: 487-497. 2011

Karvinen H, Pasanen E, Rissanen T, Korpisalo P, Vähäkangas E, Jazwa A, Giacca M, Ylä-Herttuala S.. 2011. Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle GENE THERAPY 18: 1166-1172. 2011

Korpisalo P, Hytönen JP, Laitinen JT, Laidinen S, Parviainen H, Karvinen H, Siponen J, Marjomäki V, Vajanto I, Rissanen TT, Ylä-Herttuala S.. 2011. Capillary enlargement, not sprouting angiogenesis, determines beneficial therapeutic effects and side effects of angiogenic gene therapy EUROPEAN HEART JOURNAL 32: 1664-1672. 2011

Lesch HP, Kaikkonen MU, Pikkarainen JT & Ylä-Herttuala S. 2010. Avidin-biotin technology in targeted therapy. EXPERT OPINION ON DRUG DELIVERY 7: 551-564. 2010

Nilsson I, Bahram F, Li X, Gualandi L, Koch S, Jarvius M, Söderberg O, Anisimov A, Kholová I, Pytowski B et al. 2010. VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts EMBO JOURNAL 29: 1377-1388. 2010

Lämsä V, Levonen AL, Leinonen H, Ylä-Herttuala S, Yamamoto M & Hakkola J. 2010. Cytochrome P450 2A5 constitutive expression and induction by heavy metals is dependent on redox-sensitive transcription factor Nrf2 in liver. CHEMICAL RESEARCH IN TOXICOLOGY 23: 977-985. 2010

Matilainen JM, Husso T, Toropainen S, Seuter S, Turunen MP, Gynther P, Ylä-Herttuala S, Carlberg C, Väisänen S.. 2010. Primary effect of 1α,25(OH)(2)D(3) on IL-10 expression in monocytes is short-term down-regulation. BIOCHIMICA ET BIOPHYSICA ACTA - MOLECULAR CELL RESEARCH 1803 11: 1276-1286. 2010

Mähönen AJ, Makkonen KE, Laakkonen JP, Ihalainen TO, Kukkonen SP, Kaikkonen MU, Vihinen-Ranta M, Ylä-Herttuala S & Airenne KJ. 2010. Culture medium induced vimentin reorganization associates with enhanced baculovirus-mediated gene delivery. JOURNAL OF BIOTECHNOLOGY 145: 111-119. 2010

Mäkinen PI, Lappalainen JP, Heinonen SE, Leppänen P, Lähteenvuo MT, Aarnio JV, Heikkilä J, Turunen MP & Ylä-Herttuala S. 2010. Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors CARDIOVASCULAR RESEARCH 88: 530-538. 2010

Sallinen H, Anttila M, Gröhn O, Koponen J, Hämäläinen K, Kholova I, Kosma VM, Heinonen S, Alitalo K & Ylä-Herttuala S. 2010. Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice. CANCER GENE THERAPY 18 2: 100-109. 2010

Nykänen AI, Sandelin H, Krebs R, Keränen MA, Tuuminen R, Kärpänen T, Wu Y, Pytowski B, Koskinen PK, Ylä-Herttuala S et al. 2010. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. CIRCULATION 121: 1413-1422. 2010

Roy H, Bhardwaj S, Babu M, Lähteenvuo JE & Ylä-Herttuala S. 2010. VEGF-DdeltaNdeltaC mediated angiogenesis in skeletal muscles of diabetic WHHL rabbits. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 40: 422-432. 2010

Sallinen H, Heikura T, Laidinen S, Kosma V-M, Heinonen S, Ylä-Herttuala S & Anttila M. 2010. Preoperative angiopoietin-2 serum levels. A marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 20 9: 1498-1505. 2010

Samaranayake H, Määttä AM, Pikkarainen J & Ylä-Herttuala S.. 2010. Future prospects and challenges of antiangiogenic cancer gene therapy HUMAN GENE THERAPY 21: 381-396. 2010

Yanev P, Jolkkonen J, Airenne KJ, Ylä-Herttuala S & Wirth T. 2010. Enhanced angiogenesis and reduced infarct size by vascular endothelial growth factor D is not translated to behavioral outcome in a rat model of ischemic stroke. JOURNAL OF EXPERIMENTAL STROKE & TRANSLATIONAL MEDICINE 3: 1-12. 2010

Schenkwein D, Turkki V, Kärkkäinen HR, Airenne K & Ylä-Herttuala S. 2010. Production of HIV-1 integrase fusion protein-carrying lentiviral vectors for gene therapy and protein transduction. HUMAN GENE THERAPY 21: 589-602. 2010

Korpisalo P & Ylä-Herttuala S. 2010. Stimulation of functional vessel growth by gene therapy. Integrative Biology 2: 102-112. 2010

Laitinen IEK, Luoto P, Någren K, Marjamäki PM, Silvola JMU, Hellberg S, Laine VJO, Ylä-Herttuala S, Knuuti J & Roivainen A. 2010. Uptake of 11C-choline in mouse atherosclerotic plaques. JOURNAL OF NUCLEAR MEDICINE 51: 798-802. 2010

Huhtala T, Laakkonen P, Sallinen H, Ylä-Herttuala S & Närvänen A. 2010. In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.. NUCLEAR MEDICINE AND BIOLOGY 37 8: 953-963. 2010

Kivelä AM, Mäkinen PI, Jyrkkänen HK, Mella-Aho E, Xia Y, Kansanen E, Leinonen H, Verma IM, Ylä-Herttuala S & Levonen AL. 2010. Sulforaphane inhibits endothelial lipase expression through NF-κB in endothelial cells. ATHEROSCLEROSIS 213: 122-128. 2010

Airenne KJ, Makkonen K-E, Mähönen AJ & Ylä-Herttuala S. 2010. In vivo application and tracking of baculovirus. CURRENT GENE THERAPY 10: 187-194. 2010

Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, Silvola J, Saraste A, Jeltsch M, Korpisalo P et al. 2010. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation CIRCULATION 122: 1725-1733. 2010

Hagberg CE, Falkevall A, Wang X, Larsson E, Huusko J, Nilsson I, van Meeteren LA, Samen E, Lu L, Vanwildemeersch M et al. 2010. Vascular endothelial growth factor B controls endothelial fatty acid uptake NATURE (LONDON) 464: 917-921. 2010

Cohen-Haguenauer O, Creff N, Cruz P, Tunc C, Aïuti A, Baum C, Bosch F, Blomberg P, Cichutek K & Collins M. 2010. Relevance of an academic GMP Pan-European vector infra-structure (PEVI) CURRENT GENE THERAPY 10: 414-422. 2010

Hukkanen V, Hemminki A & Ylä-Herttuala S. 2010. Geenihoito ja molekyylivirologian muut sovellukset, Mikrobiologia. 706-715. 2010

Huusko J, Merentie M, Dijkstra MH, Ryhänen M-M, Karvinen H, Rissanen TT, Vanwildemeersch M, Hedman M, Lipponen J, Heinonen SE et al. 2010. The effects of VEGF-R1 and VEGF-R2 ligands on angiogenic responses and left ventricular function in mice CARDIOVASCULAR RESEARCH 86: 122-130. 2010

Ihalainen TO, Laakkonen JP, Paloheimo O, Ylä-Herttuala S, Airenne KJ & Vihinen-Ranta M. 2010. Morphological characterization of baculovirus Autographa californica multiple nucleopolyhedrovirus. Virus Research 148: 71-74. 2010

Jazwa A, Kucharzewska P, Leja J, Zagorska A, Sierpniowska A, Stepniewski J, Kozakowska M, Taha H, Ochiya T, Derlacz R et al. 2010. Combined vascular endothelial growth factor-A and fibroblast growth factor 4 gene transfer improves wound healing in diabetic mice. Genetic Vaccines and Therapy 8: 1-16. 2010

Kaikkonen MU, Maatta AI, Ylä-Herttuala S & Airenne KJ. 2010. Screening of complement inhibitors: shielded baculoviruses increase the safety and efficacy of gene delivery. MOLECULAR THERAPY 18: 987-992. 2010

Karvinen H & Ylä-Herttuala S. 2010. New aspects in vascular gene therapy. CURRENT OPINION IN PHARMACOLOGY 2: 208-211. 2010

Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, Repici A, Sturm A, Malesci A, Panes J, Yla-Herttuala S, Fiocchi C, Danese S. 2009. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis GASTROENTEROLOGY 136: 585-595. 2009

Lähteenvuo JE, Lähteenvuo MT, Kivelä A, Rosenlew C, Falkevall A, Klar J, Heikura T, Rissanen TT, Vähäkangas E, Korpisalo P, Enholm B, Carmeliet P, Alitalo K, Eriksson U, Ylä-Herttuala S. 2009. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms CIRCULATION 119: 845-856. 2009

Määttä AM, Samaranayake H, Pikkarainen J, Wirth T, Ylä-Herttuala S. 2009. Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. CURRENT GENE THERAPY 9: 356-367. 2009

Norrmén C, Ivanov KI, Cheng J, Zangger N, Delorenzi M, Jaquet M, Miura N, Puolakkainen P, Horsley V, Hu J, Augustin HG, Ylä-Herttuala S, Alitalo K, Petrova TV. 2009. FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. JOURNAL OF CELL BIOLOGY 185 3: 439-457. 2009

Roy H, Bhardwaj S, Yla-Herttuala S. 2009. Molecular genetics of atherosclerosis HUMAN GENETICS 125: 467-491. 2009

Lesch HP, Pikkarainen JT, Kaikkonen MU, Taavitsainen M, Samaranayake H, Lehtolainen-Dalkilic P, Vuorio T, Määttä A-M, Wirth T, Airenne KJ, Ylä-Herttuala S. 2009. Avidin fusion protein-expressing lentiviral vector for targeted drug delivery. HUMAN GENE THERAPY 20: 871-882. 2009

Samaranayake H, Wirth T, Schenkwein D, Räty JK, Ylä-Herttuala S. 2009. Challenges in monoclonal antibody-based therapies. Annals of Medicine 41 5: 322-331. 2009

Ylä-Herttuala S. 2009. Geenihoito. DUODECIM 125: 1729-1739. 2009

Toivanen PI, Nieminen T, Viitanen L, Alitalo A, Roschier M, Jauhiainen S, Markkanen JE, Laitinen OH, Airenne TT, Salminen TA, Johnson MS, Airenne KJ, Ylä-Herttuala S. 2009. Novel vascular endothelial growth factor D variants with increased biological activity. JOURNAL OF BIOLOGICAL CHEMISTRY 284 23: 16037-16048. 2009

Turunen MP, Aavik E, Ylä-Herttuala S. 2009. Epigenetics and atherosclerosis. BIOCHIMICA ET BIOPHYSICA ACTA - GENERAL SUBJECTS 1790: 886-891. 2009

Turunen MP, Lehtola T, Heinonen SE, Assefa GS, Korpisalo P, Girnary R, Glass CK, Väisänen S, Ylä-Herttuala S. 2009. Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy. CIRCULATION RESEARCH 105: 604-609. 2009

Vajanto I, Korpisalo P, Karjalainen J, Hakala T, Mäkinen K, Ylä-Herttuala S. 2009. Antegrade flow and peripheral resistance determine the level of endogenous arteriogenesis in patients with superficial femoral artery occlusion. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 39: 1048-1054. 2009

Viita H, Kinnunen K, Eriksson E, Lähteenvuo J, Babu M, Kalesnykas G, Heikura T, Laidinen S, Takalo T, Ylä-Herttuala S. 2009. Intravitreal adenoviral 15-lipoxygenase- 1 gene transfer prevents vascular endothelial growth factor A-induced neovascularization in rabbit eyes. HUMAN GENE THERAPY 20: 1679-1686. 2009

Wirth T, Samaranayake H, Pikkarainen J, Määttä A-M, Ylä-Herttuala S. 2009. Clinical trials for glioblastoma multiforme using adenoviral vectors. CURRENT OPINION IN MOLECULAR THERAPEUTICS 11: 485-492. 2009

Ylä-Herttuala S. 2009. Gene therapy with vascular endothelial growth factors. BIOCHEMICAL SOCIETY TRANSACTIONS 37: 1198-1200. 2009

Zhang F, Tang Z, Hou X, Lennartsson J , Li Y, Koch AW, Scotney P, Lee C, Arjunan P, Dong L, Kumar A, Rissanen TT, Wang B, Nagai N, Fons P, Fariss R, Zhang Y, Wawrousek E, Tansey G, Raber J, Fong G-H, Ding H, Greenberg DA, Becker KG, Herbert J-M. 2009. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 106 15: 6152-6157. 2009

Loboda A, Stachurska A, Florczyk U, Rudnicka D, Jazwa A, Wegrzyn J, Kozakowska M, Stalinska K, Poellinger L, Levonen A-L, Yla-Herttuala S, Jozkowicz A, Dulak J. 2009. HIF-1 induction attenuates Nrf2-dependent IL-8 expression in human endothelial cells. ANTIOXIDANTS AND REDOX SIGNALING 11: 1501-1517. 2009

Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma V-M, Heinonen S, Alitalo K, Yla-Herttuala S. 2009. Antiangiogenic gene therapy with soluble VEGFR-1, -2 and -3 reduces the growth of solid human ovarian carcinoma in mice. MOLECULAR THERAPY 17 2: 278-284. 2009

Langford G, Dayan A, Yla-Herttuala S, Eckland D. 2009. A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (Cerepro(R)) after intracerebral administration JOURNAL OF GENE MEDICINE 11: 468-476. 2009

Kansanen E, Jyrkkänen H-K, Volger OL, Leinonen H, Kivelä AM, Häkkinen S-K, Woodcock SR, Schopfer FJ, Horrevoets AJ, Ylä-Herttuala S, Freeman BA, Levonen A-L. 2009. Nrf2-dependent and -independent responses to nitro-fatty acids in human endothelial cells: identification of heat shock response as the major pathway activated by nitro-oleic acid. JOURNAL OF BIOLOGICAL CHEMISTRY 284 48: 33233-33241. 2009

Laitinen I, Saraste A, Weidl E, Poethko T, Weber AW, Nekolla SG, Leppänen P, Ylä-Herttuala S, Hölzlwimmer G, Walch A, Esposito I, Wester H-J, Knuuti J, Schwaiger M. 2009. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice 2: 331-338. 2009

Airenne KJ, Mähönen AJ, Laitinen OH, Ylä-Herttuala S. 2009. Baculovirus-mediated gene transfer: An emerging universal concept. In: Templeton NS (ed.) , Gene and Cell Therapy. Therapeutic Mechanisms and Stragegies.Taylor and Francis. ss. 263-291. 2009

Haukkala J, Laitinen I, Luoto P, Iveson P, Wilson I, Karlsen H, Cuthbertson A, Laine J, Leppänen P, Ylä-Herttula S, Knuuti J, Roivainen A. 2009. (68)Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 36: 2058-2067. 2009

Hedman M, Muona K, Hedman A, Kivelä A, Syvänne M, Eränen J, Rantala A, Stjernvall J, Nieminen MS, Hartikainen J, Ylä-Herttuala S. 2009. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. GENE THERAPY 16: 629-634. 2009

Kaikkonen MU, Lesch HP, Pikkarainen J, Räty JK, Vuorio T, Huhtala T, Taavitsainen M, Laitinen T, Tuunanen P, Gröhn O, Närvänen A, Airenne KJ, Ylä-Herttuala S. 2009. (Strept)avidin-displaying lentiviruses as versatile tools for targeting and dual imaging of gene delivery. GENE THERAPY 16: 894-904. 2009

Kangasniemi L, Koskinen M, Jokinen M, Toriseva M, Ala-Aho R, Kähäri V-M, Jalonen H, Ylä-Herttuala S, Moilanen H, Stenman U-H, Diaconu I, Kanerva A, Pesonen S, Hakkarainen T, Hemminki A. 2009. Extended release of adenovirus from silica implants in vitro and in vivo. GENE THERAPY 16: 103-110. 2009

Kanninen K, Heikkinen R, Malm T, Rolova T, Kuhmonen S, Leinonen H, Ylä-Herttuala S, Tanila H, Levonen AL, Koistinaho M, Koistinaho J. 2009. Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 106 38: 16505-16510. 2009

Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppänen V-M, Jeltsch M, Ylä-Herttuala S, Alitalo K. 2009. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle CIRCULATION RESEARCH 104: 1302-1312. 2009

Karvinen H, Rutanen J, Leppänen O, Lach R, Levonen A-L, Eriksson U, Ylä-Herttuala S. 2009. PDGF-C and -D and their receptors PDGFR-alpha and PDGFR-beta in atherosclerotic human arteries. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 39 4: 320-327. 2009

Kinnunen K, Puustjärvi T, Teräsvirta M, Nurmenniemi P, Heikura T, Laidinen S, Paavonen T, Uusitalo H, Ylä-Herttuala S, Kinnunen K. 2009. Differences in retinal neovascular tissue and vitreous humour in patients with type 1 and type 2 diabetes. BRITISH JOURNAL OF OPHTHALMOLOGY 93: 1109-1115. 2009

Kärkkäinen A-M, Kotimaa A, Huusko J, Kholova I, Heinonen SE, Stefanska A, Dijkstra MH, Purhonen H, Hämäläinen E, Mäkinen PI, Turunen MP, Ylä-Herttuala S. 2009. Vascular endothelial growth factor-D transgenic mice show enhanced blood capillary density, improved postischemic muscle regeneration, and increased susceptibility to tumor formation. BLOOD 113: 4468-4475. 2009

Kärkkäinen H-R, Lesch HP, Määttä AI, Toivanen PI, Mähönen AJ, Roschier MM, Airenne KJ, Laitinen OH, Ylä-Herttuala S. 2009. A 96-well format for a high-throughput baculovirus generation, fast titering and recombinant protein production in insect and mammalian cells. BMC RESEARCH NOTES (ONLINE) 2: 63. 2009

Laakkonen JP, Mäkelä AR, Kakkonen E, Turkki P, Kukkonen S, Peränen J, Ylä-Herttuala S, Airenne KJ, Oker-Blom C, Vihinen-Ranta M, Marjomäki V. 2009. Clathrin-independent entry of baculovirus triggers uptake of E. coli in non-phagocytic human cells PLOS ONE [ONLINE] 4 4: e5093. 2009

Lahtinen L, Huusko N, Myöhänen H, Lehtivarjo AK, Pellinen R, Turunen MP, Ylä-Herttuala S, Pirinen E, Pitkänen A. 2009. Expression of urokinase-type plasminogen activator receptor is increased during epileptogenesis in the rat hippocampus. NEUROSCIENCE 163: 316-328. 2009

Laitinen I, Marjamäki P, Någren K, Laine VJO, Wilson I, Leppänen P, Ylä-Herttuala S, Roivainen A, Knuuti J. 2009. Uptake of inflammatory cell marker [(11)C]PK11195 into mouse atherosclerotic plaques EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 36: 73-80. 2009

Kinnunen K, Kalesnykas G, Mähönen AJ, Laidinen S, Holma L, Heikura T, Airenne K, Uusitalo H, Ylä-Herttuala S, Kinnunen K, Kalesnykas G. 2009. Baculovirus is an efficient vector for the transduction of the eye: comparison of baculovirus- and adenovirus-mediated intravitreal vascular endothelial growth factor D gene transfer in the rabbit eye. JOURNAL OF GENE MEDICINE 11: 382-389. 2009

Pulkkinen K, Malm T, Turunen M, Koistinaho J, Ylä-Herttuala S. 2008. Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS LETTERS 582: 2397-2401. 2008

Laurema A, Riekkinen M, Heikura T, Vähäkangas E, Manninen H, Heinonen S, Ylä-Herttuala S. 2008. The administration of an adenoviral thymidine kinase suicide gene to the uterine artery of rabbits does not affect fertility: a safety study of pregnant and nonpregnant rabbits and their offspring. JOURNAL OF GENE MEDICINE 10: 1005-1011. 2008

Lesch HP, Turpeinen S, Niskanen EA, Mähönen AJ, Airenne KJ, Ylä-Herttuala S. 2008. Generation of lentivirus vectors using recombinant baculoviruses. GENE THERAPY 15: 1280-1286. 2008

Levonen A-L, Vähäkangas E, Koponen JK, Ylä-Herttuala S. 2008. Antioxidant gene therapy for cardiovascular disease: current status and future perspectives. CIRCULATION 117: 2142-2150. 2008

Liimatainen TJ, Erkkilä AT, Valonen P, Vidgren H, Lakso M, Wong G, Gröhn OHJ, Ylä-Herttuala S, Hakumäki JM. 2008. 1H MR spectroscopic imaging of phospholipase-mediated membrane lipid release in apoptotic rat glioma in vivo. MAGNETIC RESONANCE IN MEDICINE 59: 1232-1238. 2008

Odermarsky M, Andersson S, Pesonen E, Sjöblad S, Ylä-Herttuala S, Liuba P. 2008. Respiratory infection recurrence and passive smoking in early atherosclerosis in children and adolescents with type 1 diabetes. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 38 6: 381-388. 2008

Tammela T , Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M, Waltari M , Hellström M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G., Ylä-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C. 2008. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. NATURE (LONDON) 454: 656-660. 2008

Purhonen S, Palm J, Rossi D, Kaskenpää N, Rajantie I, Ylä-Herttuala S, Alitalo K, Weissman IL, Salven P. 2008. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 105 18: 6620-6625. 2008

Rissanen TT, Korpisalo P, Karvinen H, Liimatainen T, Laidinen S, Gröhn OH, Ylä-Herttuala S. 2008. High-resolution ultrasound perfusion imaging of therapeutic angiogenesis. JACC: CARDIOVASCULAR IMAGING 1 1: 83 - 91. 2008

Räty JK, Lesch HP, Wirth T, Ylä-Herttuala S. 2008. Improving safety of gene therapy. CURRENT DRUG SAFETY 3 1: 46-53. 2008

Sierra A, Michaeli S, Niskanen J-P, Valonen PK, Gröhn HI, Ylä-Herttuala S, Garwood M, Gröhn OH. 2008. Water spin dynamics during apoptotic cell death in glioma gene therapy probed by T1rho and T2rho. MAGNETIC RESONANCE IN MEDICINE 59: 1311-1319. 2008

Tuomisto TT, Lumivuori H, Kansanen E, Häkkinen S-K, Turunen MP, van Thienen JV, Horrevoets AJ, Levonen A-L, Ylä-Herttuala S. 2008. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. CARDIOVASCULAR RESEARCH 78 1: 175-184. 2008

Viita H, Markkanen J, Eriksson E, Nurminen M, Kinnunen K, Babu M, Heikura T, Turpeinen S, Laidinen S, Takalo T, Ylä-Herttuala S. 2008. 15-lipoxygenase-1 prevents vascular endothelial growth factor A- and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels, NO bioactivity, and downregulation of VEGF receptor 2 expression. CIRCULATION RESEARCH 102: 177-184. 2008

Korpisalo P, Rissanen TT, Bengtsson T, Liimatainen T, Laidinen S, Karvinen H, Markkanen JE, Gröhn OH, Ylä-Herttuala S. 2008. Therapeutic angiogenesis with placental growth factor improves exercise tolerance of ischaemic rabbit hindlimbs. CARDIOVASCULAR RESEARCH 80 2: 263-270. 2008

Laakkonen JP, Kaikkonen MU, Ronkainen PHA, Ihalainen TO, Niskanen EA, Häkkinen M, Salminen M, Kulomaa MS, Ylä-Herttuala S, Airenne KJ, Vihinen-Ranta M. 2008. Baculovirus-mediated immediate-early gene expression and nuclear reorganization in human cells. CELLULAR MICROBIOLOGY 10 3: 667-681. 2008

Saraste A, Kytö V, Laitinen I, Saraste M, Leppänen P, Ylä-Herttuala S, Saukko P, Hartiala J, Knuuti J. 2008. Severe coronary artery stenoses and reduced coronary flow velocity reserve in atherosclerotic mouse model Doppler echocardiography validation study. ATHEROSCLEROSIS 200: 89-94. 2008

Korpisalo P, Karvinen H, Rissanen TT, Kilpijoki J, Marjomäki V, Baluk P, McDonald DM, Cao Y, Eriksson U, Alitalo K, Ylä-Herttuala S. 2008. Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic. CIRCULATION RESEARCH 103: 1092-1099. 2008

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K. 2008. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. CANCER RESEARCH 68: 4754-4762. 2008

Kivelä AM, Kansanen E, Jyrkkänen HK, Nurmi T, Ylä-Herttuala S, Levonen AL. 2008. Enterolactone induces heme oxygenase-1 expression through nuclear factor-E2-related factor 2 activation in endothelial cells. JOURNAL OF NUTRITION 138: 1263-1268. 2008

Bhardwaj S, Roy H, Ylä-Herttuala S. 2008. Gene therapy to prevent occlusion of venous bypass grafts EXPERT REVIEW OF CARDIOVASCULAR THERAPY 6 5: 641-652. 2008

Botusan IR, Sunkari VG, Savu O, Catrina AI, Grünler J, Lindberg S, Pereira T, Ylä-Herttuala S, Poellinger L, Brismar K, Catrina SB. 2008. Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 105 49: 19426-19431. 2008

Dworakowski R, Dworakowska D, Kocic I, Wirth T, Gruchala M, Kaminski M, Ray R, Petrusewicz J, Yla-Herttuala S, Rynkiewicz A. 2008. Experimental hyperlipidaemia does not prevent preconditioning and it reduces ischemia-induced apoptosis. INTERNATIONAL JOURNAL OF CARDIOLOGY 126: 62-67. 2008

Aggarwal NT, Chawengsub Y, Gauthier KM, Viita H, Yla-Herttuala S, Campbell WB. 2008. Endothelial 15-lipoxygenase-1 overexpression increases acetylcholine-induced hypotension and vasorelaxation in rabbits. HYPERTENSION 51: 246-251. 2008

Fledderus JO, Boon RA, Volger OL, Hurttila H, Ylä-Herttuala S, Pannekoek H, Levonen A-L, Horrevoets AJG. 2008. KLF2 primes the antioxidant transcription factor Nrf2 for activation in endothelial cells. ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY 28: 1339-1346. 2008

Benest AV, Harper SJ, Yla Herttuala S, Alitalo K, Bates DO. 2008. VEGF-C induced angiogenesis preferentially occurs at a distance from lymphangiogenesis. CARDIOVASCULAR RESEARCH 78: 315-323. 2008

Hurttila H, Koponen JK, Kansanen E, Jyrkkänen H-K, Kivelä A, Kylätie R, Ylä-Herttuala S, Levonen A-L. 2008. Oxidative stress-inducible lentiviral vectors for gene therapy. GENE THERAPY 15: 1271-1279. 2008

Jyrkkänen H-K, Kansanen E, Inkala M, Kivelä AM, Hurttila H, Heinonen SE, Goldsteins G, Jauhiainen S, Tiainen S, Makkonen H, Oskolkova O, Afonyushkin T, Koistinaho J, Yamamoto M, Bochkov VN, Ylä-Herttuala S, Levonen A-L. 2008. Nrf2 regulates antioxidant gene expression evoked by oxidized phospholipids in endothelial cells and murine arteries in vivo CIRCULATION RESEARCH [ONLINE: HTTP://CIRCRES.AHAJOURNALS.ORG/] 103: e1-e9. 2008

Kaikkonen MU, Viholainen JI, Närvänen A, Ylä-Herttuala S, Airenne KJ. 2008. Targeting and purification of metabolically biotinylated baculovirus. HUMAN GENE THERAPY 19 6: 589-600. 2008

Kanninen K, Malm TM, Jyrkkänen HK, Goldsteins G, Keksa-Goldsteine V, Tanila H, Yamamoto M, Ylä-Herttuala S, Levonen AL, Koistinaho J. 2008. Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. MOLECULAR AND CELLULAR NEUROSCIENCE (SAN DIEGO CA) 39 3: 302-313. 2008

Karpanen T, Bry M, Ollila HM, Seppänen-Laakso T, Liimatta E, Leskinen H, Kivelä R, Helkamaa T, Merentie M, Jeltsch M, Paavonen K, Andersson LC, Mervaala E, Hassinen IE, Ylä-Herttuala S, Oresic M, Alitalo K. 2008. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. CIRCULATION RESEARCH 103: 1018-1026. 2008

Kirjavainen A, Sulg M, Heyd F, Alitalo K, Ylä-Herttuala S, Möröy T, Petrova TV, Pirvola U. 2008. Prox1 interacts with Atoh1 and Gfi1, and regulates cellular differentiation in the inner ear sensory epithelia DEVELOPMENTAL BIOLOGY 332: 33-45. 2008

Huusko J, Mäkinen PI, Alhonen L, Ylä-Herttuala S. 2008. Generation of transgenic and knockdown mice with lentiviral vectors and RNAi techniques: Latterich M, RNAi.Taylor & Francis. 91-111. 2008

Tammela T, He Y, Lyytikkä J, Jeltsch M, Markkanen J, Pajusola K, Ylä-Herttuala S, Alitalo K. 2007. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins. CIRCULATION RESEARCH 100 10: 1468-1475. 2007

Rissanen TT, Ylä-Herttuala S. 2007. Uudisverisuonten kasvattaminen - kohti iskeemisten kudosten parempaa verenkiertoa. DUODECIM 123: 306-316. 2007

Räty JK, Liimatainen T, Huhtala T, Kaikkonen MU, Airenne KJ, Hakumäki JM, Närvänen A, Ylä-Herttuala S. 2007. SPECT/CT imaging of baculovirus biodistribution in rat. GENE THERAPY 14: 930-938. 2007

Räty JK, Liimatainen T, Kaikkonen MU, Gröhn O, Airenne KJ, Ylä-Herttuala S. 2007. Non-invasive imaging in gene therapy. MOLECULAR THERAPY 15 9: 1579-1586. 2007

Sipola A, Ilvesaro J, Birr E, Jalovaara P, Pettersson RF, Stenbäck F, Ylä-Herttuala S, Hautala T, Tuukkanen J. 2007. Endostatin inhibits endochondral ossification JOURNAL OF GENE MEDICINE 9 12: 1057-1064. 2007

Ylä-Herttuala S, Alitalo K. 2007. On the relationship of LDL and VEGFR1: not just a family affair. EMBO REPORTS 8 12: 1127-1128. 2007

Tammela T, Saaristo A, Holopainen T, Lyytikkä J, Kotronen A, Pitkonen M, Abo-Ramadan U, Ylä-Herttuala S, Petrova TV, Alitalo K. 2007. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation NATURE MEDICINE 13: 1458-1466. 2007

Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, Nagy JA, Dvorak HF, Ylä-Herttuala S, Shibuya M, Alitalo K. 2007. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. JOURNAL OF EXPERIMENTAL MEDICINE 204 6: 1431-1440. 2007

Yan D, Lehto M, Rasilainen L, Metso J, Ehnholm C, Ylä-Herttuala S, Jauhiainen M, Olkkonen VM. 2007. Oxysterol binding protein induces upregulation of SREBP-1c and enhances hepatic lipogenesis. ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY 27: 1108-1114. 2007

Ylä-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. 2007. Vascular endothelial growth factors. Biology and current status of clinical applications in cardiovascular medicine. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 49 10: 1015-1026. 2007

Ylä-Herttuala S. 2007. Peripheral vascular diseases. In Review: Progress and prospects: gene therapy clinical trials (Part 1) GENE THERAPY 14: 1445-1447. 2007

Ylä-Herttuala S. 2007. Principles of gene medicines. EJHP PRACTICE JOURNAL [HTTP://WWW.EAHPONLINE.COM/] 13 5: 18-19. 2007

Pirinen E, Kuulasmaa T, Pietilä M, Heikkinen S, Tusa M, Itkonen P, Boman S, Skommer J, Virkamäki A, Hohtola E, Kettunen M, Fatrai S, Kansanen E, Koota S, Niiranen K, Parkkinen J, Levonen A-L, Ylä-Herttuala S, Hiltunen JK, Alhonen L, Smith U, Jänne J. 2007. Enhanced polyamine catabolism alters homeostatic control of white adipose tissue mass, energy expenditure, and glucose metabolism MOLECULAR AND CELLULAR BIOLOGY 27 13: 4953-4967. 2007

Rissanen TT, Ylä-Herttuala S. 2007. Current status of cardiovascular gene therapy. MOLECULAR THERAPY 15 7: 1233-1247. 2007

Levonen A-L, Inkala M, Heikura T, Jauhiainen S, Jyrkkänen H-K, Kansanen E, Määttä K, Romppanen E, Turunen P, Rutanen J, Ylä-Herttuala S. 2007. Nrf2 gene transfer induces antioxidant enzymes and suppresses smooth muscle cell growth in vitro and reduces oxidative stress in rabbit aorta in vivo. ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY 27: 741-747. 2007

Mähönen AJ, Airenne KJ, Purola S, Peltomaa E, Kaikkonen MU, Riekkinen MS, Heikura T, Kinnunen K, Roschier MM, Wirth T, Ylä-Herttuala S. 2007. Post-transcriptional regulatory element boosts baculovirus-mediated gene expression in vertebrate cells. JOURNAL OF BIOTECHNOLOGY 131 1: 1-8. 2007

Helppolainen SH, Nurminen KP, Määttä JAE, Halling KK, Slotte JP, Huhtala T, Liimatainen T, Ylä-Herttuala S, Airenne KJ, Närvänen A, Jänis J, Vainiotalo P, Valjakka J, Kulomaa MS, Nordlund HR. 2007. Rhizavidin from Rhizobium etli: the first natural dimer in the avidin protein family BIOCHEMICAL JOURNAL 405: 397-405. 2007

Aggarwal NT, Holmes BB, Cui L, Viita H, Yla-Herttuala S, Campbell WB. 2007. Adenoviral expression of 15-lipoxygenase-1 in rabbit aortic endothelium: role in arachidonic acid-induced relaxation. AMERICAN JOURNAL OF PHYSIOLOGY. HEART AND CIRCULATORY PHYSIOLOGY 292: H1033-H1041. 2007

Lucerna M, Zernecke A, de Nooijer R, de Jager SC, Bot I, van der Lans C, Kholova I, Liehn EA, van Berkel TJC, Yla-Herttuala S, Weber C, Biessen EAL. 2007. Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. BLOOD 109 1: 122-129. 2007

Back J, Kankuri E, Ikonen T, Pätilä T, Sinisalo J, Laine M, Vapaatalo H, Koponen J, Hukkanen M, Ylä-Herttuala S, Alitalo R, Kupari M, Harjula A. 2007. Solusiirrot sydämen vajaatoiminnan hoidossa. DUODECIM 123: 398-405. 2007

Bräsen JH, Leppänen O, Inkala M, Heikura T, Levin M, Ahrens F, Rutanen J, Pietsch H, Bergqvist D, Levonen A-L, Basu S, Zeller T, Klöppel G, Laukkanen MO, Ylä-Herttuala S. 2007. Extracellular superoxide dismutase accelerates endothelial recovery and inhibits in-stent restenosis in stented atherosclerotic Watanabe heritable hyperlipidemic rabbit aorta. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 50 23: 2249-2253. 2007

Heinonen SE, Leppänen P, Kholová I, Lumivuori H, Häkkinen S-K, Bosch F, Laakso M, Ylä-Herttuala S, Kholova I, Laakso M. 2007. Increased atherosclerotic lesion calcification in a novel mouse model combining insulin resistance, hyperglycemia, and hypercholesterolemia. CIRCULATION RESEARCH 101: 1058-1067. 2007

Airenne KJ, Laitinen OH, Mähönen AJ. 2007. Safe, simple, and high-capacity gene delivery into insect and vertebrate cells by recombinant baculoviruses: Friedmann T, Rossi J, Gene Transfer. Delivery and Expression of DNA and RNA. A Laboratory Manual.Gold Spring Harbor. 313-325. 2007

Keskitalo S, Tammela T, Lyytikka J, Karpanen T, Jeltsch M, Markkanen J, Yla-Herttuala S, Alitalo K. 2007. Enhanced capillary formation stimulated by a chimeric vascular endothelial growth factor/vascular endothelial growth factor-C silk domain fusion protein. CIRCULATION RESEARCH 100 10: 1460-1467. 2007

Kholová I, Koota S, Kaskenpää N, Leppänen P, Närväinen J, Kavec M, Rissanen TT, Hazes T, Korpisalo P, Gröhn O, Ylä-Herttuala S. 2007. Adenovirus-mediated gene transfer of human vascular endothelial growth factor-d induces transient angiogenic effects in mouse hind limb muscle. HUMAN GENE THERAPY 18: 232-244. 2007

Koponen JK, Kekarainen T, Heinonen SE, Laitinen A, Nystedt J, Laine J, Ylä-Herttuala S. 2007. Umbilical cord blood-derived progenitor cells enhance muscle regeneration in mouse hindlimb ischemia model MOLECULAR THERAPY 15 12: 2172-2177. 2007

Korpisalo P, Rissanen TT, Ylä-Herttuala S. 2007. The strengths and weaknesses of VEGF adenovirus-driven angiogenesis: Deindl E, Kupatt C, Therapeutic Neovascularization - Quo Vadis?.Springer. 23-32. 2007

Laurema A, Lumme S, Heinonen SE, Heinonen S, Ylä-Herttuala S. 2007. Transduction patterns and efficiencies in rabbit uterine tissues after intraluminal uterine adenovirus administration vary with the reproductive cycle ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA 86 9: 1035-1040. 2007

Liuba P, Aburawi EH, Pesonen E, Andersson S, Truedsson L, Ylä-Herttuala S, Holmberg L. 2007. Residual adverse changes in arterial endothelial function and LDL oxidation after a mild systemic inflammation induced by influenza vaccination. Annals of Medicine 39 5: 392-399. 2007

Kettunen MI, Sierra A, Närväinen MJ, Valonen PK, Ylä-Herttuala S, Kauppinen RA, Gröhn OHJ. 2007. Low spin-lock field T1 relaxation in the rotating frame as a sensitive MR imaging marker for gene therapy treatment response in rat glioma. RADIOLOGY 243: 796-803. 2007

Sallinen H, Anttila M, Narvainen J, Ordén M-R, Ropponen K, Kosma V-M, Heinonen S, Yla-Herttuala S. 2006. A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up. GYNECOLOGIC ONCOLOGY 103 1: 315-320. 2006

Roy H, Bhardwaj S, Ylä-Herttuala S. 2006. Biology of vascular endothelial growth factors FEBS LETTERS 580 12: 2879-2887. 2006

Räty JK, Liimatainen T, Wirth T, Airenne KJ, Ihalainen TO, Huhtala T, Hamerlynck E, Vihinen-Ranta M, Närvänen A, Ylä-Herttuala S, Hakumäki JM. 2006. Magnetic resonance imaging of viral particle biodistribution in vivo. GENE THERAPY 13: 1440-1446. 2006

Saaristo A, Tammela T, Färkkilä A, Kärkkäinen M, Suominen E, Ylä-Herttuala S, Alitalo K. 2006. Vascular endothelial growth factor-C accelerates diabetic wound healing AMERICAN JOURNAL OF PATHOLOGY 169: 1080-1087. 2006

Ylä-Herttuala S, Salo M. 2006. Periytyvien tautien hoito: Aula P, Kääriäinen H, Palotie A, Perinnöllisyyslääketiede. 3. uud. p..Duodecim. 317-328. 2006

Turunen P, Puhakka HL, Heikura T, Romppanen E, Inkala M, Leppänen O, Ylä-Herttuala S. 2006. Extracellular superoxide dismutase with vaccinia virus anti-inflammatory protein 35K or tissue inhibitor of metalloproteinase-1: Combination gene therapy in the treatment of vein graft stenosis in rabbits. HUMAN GENE THERAPY 17 4: 405-414. 2006

Wirth T, Hedman M, Mäkinen K, Manninen H, Immonen A, Vapalahti M, Ylä-Herttuala S. 2006. Safety profile of plasmid/liposomes and virus vectors on clinical gene therapy. CURRENT DRUG SAFETY 1: 253-257. 2006

Wirth T, Ylä-Herttuala S. 2006. Gene technology based therapies in the brain. In: Pickard JD (ed.) . Springer. Advances and Technical Standards in Neurosurgery. s. 3-32. 2006

Ylä-Herttuala S. 2006. An update on angiogenic gene therapy: Vascular endothelial growth factor and other directions. CURRENT OPINION IN MOLECULAR THERAPEUTICS 8 4: 295-300. 2006

Roy H, Bhardwaj S, Babu M, Kokina I, Uotila S, Ahtialansaari T, Laitinen T, Hakumaki J, Laakso M, Herzig K-H, Ylä-Herttuala S. 2006. VEGF-A, VEGF-D, VEGF receptor-1, VEGF receptor-2, NF-kappaB, and RAGE in atherosclerotic lesions of diabetic Watanabe heritable hyperlipidemic rabbits [FJ Express Full-Length Article]. FASEB JOURNAL [ONLINE] 20: E1550-E1559. 2006

Roy H, Bhardwaj S, Babu M, Kokina I, Uotila S, Ahtialansaari T, Laitinen T, Hakumäki J, Laakso M, Herzig K-H, Ylä-Herttuala S. 2006. VEGF-A, VEGF-D, VEGF receptor-1, VEGF receptor-2, NF-kappaB, and RAGE in atherosclerotic lesions of diabetic Watanabe heritable hyperlipidemic rabbits FASEB JOURNAL 20: 2159-2161. 2006

Rautsi O, Lehmusvaara S, Salonen T, Häkkinen K, Sillanpää M, Hakkarainen T, Heikkinen S, Vähäkangas E, Ylä-Herttuala S, Hinkkanen A, Julkunen I, Wahlfors J, Pellinen R. 2006. Type I interferon response against viral and non-viral gene transfer in human tumor and primary cell lines. JOURNAL OF GENE MEDICINE 9 2: 122-135. 2006

Pätilä T, Ikonen T, Rutanen J, Ahonen A, Lommi J, Lappalainen K, Krogerus L, Ihlberg L, Partanen TA, Lähteenoja L, Virtanen K, Alitalo K, Ylä-Herttuala S, Harjula A. 2006. Vascular endothelial growth factor C-induced collateral formation in a model of myocardial ischemia. JOURNAL OF HEART AND LUNG TRANSPLANTATION 25 2: 206-213. 2006

Kinnunen K, Korpisalo P, Rissanen TT, Heikura T, Viita H, Uusitalo H, Ylä-Herttuala S. 2006. Overexpression of VEGF-A induces neovascularization and increased vascular leakage in rabbit eye after intravitreal adenoviral gene transfer. ACTA PHYSIOLOGICA (OXFORD) 187: 447-457. 2006

Deiner C, Schwimmbeck PL, Koehler IS, Loddenkemper C, Noutsias M, Nikol S, Schultheiss H-P, Ylä-Herttuala S, Pels K. 2006. Adventitial VEGF(165) gene transfer prevents lumen loss through induction of positive arterial remodeling after PTCA in porcine coronary arteries. ATHEROSCLEROSIS 189 1: 123-132. 2006

Gruchala M, Roy H, Bhardwaj S, Ylä-Herttuala S. 2006. Gene therapy for cardiovascular diseases: ur-Rahman A, Reitz AB, Frontiers in Medicinal Chemistry.Betham Science. 59-85. 2006

Hedman M, Turunen MP, Ylä-Herttuala S. 2006. New technologies in cardiovascular research gene therapy. In: Pasterkamp G, de Kleijn DPV (ed.) Cardiovascular Research. New Technologies, Methods, and Applications. Ei jufo-kustantaja/not jufo publisher. s. 85-101. 2006

Karpanen T, Wirzenius M, Mäkinen T, Veikkola T, Haisma HJ, Achen MG, Stacker SA, Pytowski B, Ylä-Herttuala S, Alitalo K. 2006. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation AMERICAN JOURNAL OF PATHOLOGY 169: 708-718. 2006

Kaikkonen MU, Räty JK, Airenne KJ, Wirth T, Heikura T, Ylä-Herttuala S. 2006. Truncated vesicular stomatitis virus G protein improves baculovirus transduction efficiency in vitro and in vivo. GENE THERAPY 13: 304-312. 2006

Laitinen I, Marjamäki P, Haaparanta M, Savisto N, Laine VJO, Soini SL, Wilson I, Leppänen P, Ylä-Herttuala S, Roivainen A, Knuuti J. 2006. Non-specific binding of [(18)F]FDG to calcifications in atherosclerotic plaques: experimental study of mouse and human arteries. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 33 12: 1461-1467. 2006

Leppänen P, Kholová I, Mähönen AJ, Airenne K, Koota S, Mansukoski H, Närväinen J, Wirzenius M, Alhonen L, Jänne J, Alitalo K, Ylä-Herttuala S. 2006. Short and long-term effects of hVEGF-A165 in Cre-activated transgenic mice. PLOS ONE [ONLINE] 1 e13. 2006

Mäkinen PI, Koponen JK, Kärkkäinen A-M, Malm TM, Pulkkinen KH, Koistinaho J, Turunen MP, Ylä-Herttuala S. 2006. Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. JOURNAL OF GENE MEDICINE 8 4: 433-441. 2006

Mäntylä T, Hakumäki JM, Huhtala T, Närvänen A, Ylä-Herttuala S. 2006. Targeted magnetic resonance imaging of Scavidin-receptor in human umbilical vein endothelial cells in vitro. MAGNETIC RESONANCE IN MEDICINE 55 4: 800-804. 2006

Nälsén C, Vessby B, Berglund L, Uusitupa M, Hermansen K, Riccardi G, Rivellese A, Storlien L, Erkkilä A, Ylä-Herttuala S, Tapsell L, Basu S. 2006. Dietary (n-3) fatty acids reduce plasma F2-isoprostanes but not prostaglandin F2alfa in healthy humans. JOURNAL OF NUTRITION 136: 1222-1228. 2006

Pulkkanen KJ, Yla-Herttuala S. 2006. Adenovirus-mediated HSV-tk gene therapy for malignant glioma: Clinical experience: Lowenstein PR, Castro MG, Gene Therapy for Neurological Disorders.Taylor and Francis. 327-341. 2006

Salminen M, Airenne KJ, Rinnankoski R, Reimari J, Välilehto O, Rinne J, Suikkanen S, Kukkonen S, Ylä-Herttuala S, Kulomaa MS, Vihinen-Ranta M. 2005. Improvement in nuclear entry and transgene expression of baculoviruses by disintegration of microtubules. JOURNAL OF VIROLOGY 79 5: 2720-2728. 2005

Radke PW, Griesenbach U, Kivela A, Vick T, Judd D, Munkonge F, Willis S, Geddes DM, Yla-Herttuala S, Alton EWFW. 2005. Vascular oligonucleotide transfer facilitated by a polymer-coated stent. HUMAN GENE THERAPY 16 6: 734-740. 2005

Rissanen TT, Korpisalo P, Markkanen JE, Liimatainen T, Ordén M-R, Kholová I, de Goede A, Heikura T, Gröhn OH, Ylä-Herttuala S. 2005. Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arterialization and sprouting angiogenesis CIRCULATION 112: 3937-3946. 2005

Roy H, Bhardwaj S, Babu M, Jauhiainen S, Herzig K-H, Bellu AR, Haisma HJ, Carmeliet P, Alitalo K, Ylä-Herttuala S. 2005. Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. HUMAN GENE THERAPY 16 12: 1422-1428. 2005

Ruponen M, Hyvönen Z, Urtti A, Ylä-Herttuala S. 2005. Nonviral gene delivery methods in cardiovascular diseases: Fennell JP, Baker AH, Hypertension. Methods and Protocols.Humana Press. Methods in Molecular Medicine. 315-328. 2005

Rutanen J, Turunen A-M, Teittinen M, Rissanen TT, Heikura T, Koponen JK, Gruchala M, Inkala M, Jauhiainen S, Hiltunen MO, Turunen MP, Stacker SA, Achen MG, Ylä-Herttuala S. 2005. Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism. GENE THERAPY 12: 980-987. 2005

Saaristo A, Suominen E, Yla-Herttuala S. 2005. Gene transfer as a tool to induce therapeutic vascular growth in plastic surgery. HANDCHIRURGIE, MIKROCHIRURGIE, PLASTISCHE CHIRURGIE 37: 375-382. 2005

Wu JC, Ylä-Herttuala S. 2005. Human gene therapy and imaging: cardiology 32: S346-S357. 2005

Tammela T, Saaristo A, Lohela M, Morisada T, Tornberg J, Norrmén C, Oike Y, Pajusola K, Thurston G, Suda T, Yla-Herttuala S, Alitalo K. 2005. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. BLOOD 105 2: 4642-4648. 2005

Tuomisto TT, Binder BR, Ylä-Herttuala S. 2005. Genetics, genomics and proteomics in atherosclerosis research. Annals of Medicine 37 5: 323-332. 2005

Tuomisto TT, Riekkinen MS, Viita H, Levonen A-L, Ylä-Herttuala S. 2005. Analysis of gene and protein expression during monocyte-macrophage differentation and cholesterol loading - cDNA and protein array study. ATHEROSCLEROSIS 180 2: 283-291. 2005

Tuomisto TT, Ylä-Herttuala S. 2005. What have we learnt about microarray analyses of atherogenesis?. CURRENT OPINION IN LIPIDOLOGY 16: 201-205. 2005

Turunen P, Puhakka H, Rutanen J, Hiltunen MO, Heikura T, Gruchala M, Ylä-Herttuala S. 2005. Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta ATHEROSCLEROSIS 179 1: 27-33. 2005

Vähäkangas E, Ylä-Herttuala S. 2005. Gene therapy of atherosclerosis: Starke K, Handbook of Experimental Pharmacology.Springer. 785-807. 2005

Puhakka HL, Turunen P, Rutanen J, Hiltunen MO, Turunen MP, Ylä-Herttuala S. 2005. Tissue inhibitor of metalloproteinase 1 adenoviral gene therapy alone is equally effective in reducing restenosis as combination gene therapy in a rabbit restenosis model. JOURNAL OF VASCULAR RESEARCH 42 5: 361-367. 2005

Pulkkanen KJ, Ylä-Herttuala S. 2005. Gene therapy for malignant glioma: current clinical status MOLECULAR THERAPY 12 4: 585-598. 2005

Puhakka HL, Turunen P, Gruchala M, Bursill C, Heikura T, Vajanto I, Greaves DR, Channon K, Ylä-Herttuala S. 2005. Effects of vaccinia virus anti-inflammatory protein 35K and TIMP-1 gene transfers on vein graft stenosis in rabbits. IN VIVO (ATHENS) 19: 515-522. 2005

Bhardwaj S, Roy H, Kärpänen T, Hi Y, Jauhiainen S, Hedman M, Alitalo K, Ylä-Herttuala S. 2005. Periadventitial angiopoietin-1 gene transfer induces angiogenesis in rabbit carotid arteries. GENE THERAPY 12 5: 388-394. 2005

Heikkilä A, Tuomisto T, Häkkinen S-K, Keski-Nisula L, Heinonen S, Ylä-Herttuala S. 2005. Tumor suppressor and growth regulatory genes are overexpressed in severe early-onset preeclampsia - an array study on casespecific human preeclamptic placental tissue. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA 84: 679-689. 2005

Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, Jeltsch M, Petrova TV, Pytowski B, Stacker SA, Ylä-Herttuala S, Jackson DG, Alitalo K, McDonald DM. 2005. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. JOURNAL OF CLINICAL INVESTIGATION 115: 247-257. 2005

Bhardwaj S, Roy H, Heikura T, Ylä-Herttuala S. 2005. VEGF-A, VEGF-D and VEGF-D(DeltaNDeltaC) induced intimal hyperplasia in carotid arteries. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 35 11: 669-676. 2005

Pajusola K, Künnapuu J, Vuorikoski S, Soronen J, André H, Pereira T, Korpisalo P, Ylä-Herttuala S, Poellinger L, Alitalo K. 2005. Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. FASEB JOURNAL 19 10: 1365-1367. 2005

Chaudhuri JD, Hiltunen M, Nykänen M, Ylä-Herttuala S, Soininen H, Miettinen R, Hiltunen M, Soininen H. 2005. Localization of M2 muscarinic receptor protein in parvalbumin and calretinin containing cells of the adult rat entorhinal cortex using two complementary methods. NEUROSCIENCE 131: 557-566. 2005

Dworakowska D, Jassem E, Jassem J, Karmolinski A, Dworakowski R, Wirth T, Gruchala M, Rynkiewicz A, Skokowski J, Yla-Herttuala S, Jaskiewicz K, Czestochowska E. 2005. Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21(WAF1/CIP1) protein expression. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 131 9: 617-623. 2005

Erkkilä AT, Närvänen O, Lehto S, Uusitupa MIJ, Ylä-Herttuala S. 2005. Antibodies against oxidized LDL and cardiolipin and mortality in patients with coronary heart disease. ATHEROSCLEROSIS 183: 157-162. 2005

He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. 2005. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. CANCER RESEARCH 65: 4739-4746. 2005

Katsube K, Bishop AT, Simari RD, Ylä-Herttuala S, Friedrich PF. 2005. Vascular endothelial growth factor (VEGF) gene transfer enhances surgical revascularization of necrotic bone. JOURNAL OF ORTHOPAEDIC RESEARCH 23 2: 469-474. 2005

Koponen JK, Ylä-Herttuala S. 2005. Miten saada sydänlihasarpi sykkimään?. DUODECIM 121: 1199-1201. 2005

Krebs R, Tikkanen MJ, Nykänen AI, Wood J, Jeltsch M, Ylä-Herttuala S, Koskinen PK, Lemström KB. 2005. Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 171: 1421-1429. 2005

Laitinen OH, Airenne KJ, Hytönen VP, Peltomaa E, Mähönen AJ, Wirth T, Lind MM, Mäkelä KA, Toivanen PI, Schenkwein D, Heikura T, Nordlund HR, Kulomaa MS, Ylä-Herttuala S. 2005. A multipurpose vector system for the screening of libraries in bacteria, insect and mammalian cells and expression in vivo. NUCLEIC ACIDS RESEARCH 33 4: e42. 2005

Laitinen OH, Airenne KJ, Räty JK, Wirth T, Ylä-Herttuala S. 2005. Avidin fusion protein strategies in targeted drug and gene delivery. LETTERS IN DRUG DESIGN & DISCOVERY 2: 124-132. 2005

Leppänen P, Koota S, Kholová I, Koponen J, Fieber C, Eriksson U, Alitalo K, Ylä-Herttuala S. 2005. Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic. CIRCULATION 112: 1347-1352. 2005

Luoma JS, Kareinen A, Närvänen O, Viitanen L, Laakso M, Ylä-Herttuala S. 2005. Autoantibodies against oxidized LDL are associated with severe chest pain attacks in patients with coronary heart disease FREE RADICAL BIOLOGY & MEDICINE 39: 1660-1665. 2005

Markkanen JE, Rissanen TT, Kivelä A, Ylä-Herttuala S. 2005. Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart - gene therapy CARDIOVASCULAR RESEARCH 65 3: 656-664. 2005

Tuomisto TT, Rissanen TT, Vajanto I, Korkeela A, Rutanen J, Ylä-Herttuala S. 2004. HIF-VEGF-VEGFR-2, TNF-alfa and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array. ATHEROSCLEROSIS 174: 111-120. 2004

Rutanen J, Rissanen TT, Markkanen JE, Gruchala M, Silvennoinen P, Kivelä A, Hedman A, Hedman M, Heikura T, Ordén M-R, Stacker SA, Achen MG, Hartikainen J, Ylä-Herttuala S.. 2004. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. CIRCULATION 109: 1029-1035. 2004

Rutanen J, Rissanen TT, Markkanen JE, Ylä-Herttuala S. 2004. Transmyocardial angiogenic effects after intramyocardial adenoviral catheter-mediated VEGF-A and VEGF-D gene transfer in the porcine heart. NOGA LETTER 3: 13-15. 2004

Räty JK, Airenne KJ, Marttila AT, Marjomäki V, Hytönen VP, Lehtolainen P, Laitinen OH, Mähönen AJ, Kulomaa MS, Ylä-Herttuala S. 2004. Enhanced gene delivery by avidin-displaying baculovirus. MOLECULAR THERAPY 9 2: 282-291. 2004

Saaristo A, Tammela T, Timonen J, Yla-Herttuala S, Tukiainen E, Asko-Seljavaara S, Alitalo K. 2004. Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. FASEB JOURNAL 18: 1707-1709. 2004

Tuhkanen H, Anttila M, Kosma V-M, Ylä-Herttuala S, Heinonen S, Kuronen A, Juhola M, Tammi R, Tammi M, Mannermaa A. 2004. Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p INTERNATIONAL JOURNAL OF CANCER 109 2: 247-252. 2004

Pulkkanen KJ, Sallinen H, Tyynelä K, Yla-Herttuala S. 2004. Cancer gene therapy - current status in the clinics. GENE THERAPY AND REGULATION 2 3: 219-274. 2004

Turunen P, Jalkanen J, Heikura T, Puhakka H, Karppi J, Nyyssönen K, Ylä-Herttuala S. 2004. Adenovirus-mediated gene transfer of Lp-PLA2 reduces LDL degradation and foam cell formation in vitro. JOURNAL OF LIPID RESEARCH 45: 1633-1639. 2004

Valonen PK, Lehtimäki KK, Väisänen TH, Kettunen MI, Gröhn OHJ, Ylä-Herttuala S, Kauppinen RA. 2004. Water diffusion in a rat glioma during ganciclovir-thymidine kinase gene therapy-induced programmed cell death in vivo: Correlation with cell density JOURNAL OF MAGNETIC RESONANCE IMAGING 19 4: 389-396. 2004

Ylä-Herttuala S, Dzau VJ. 2004. Introduction. EUROPEAN HEART JOURNAL. SUPPLEMENTS 6: E1. 2004

Ylä-Herttuala S, Markkanen JE, Rissanen TT. 2004. Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials TRENDS IN CARDIOVASCULAR MEDICINE 14: 295-300. 2004

Ylä-Herttuala S. 2004. Therapeutic angiogenesis: Matsuzawa Y, Kita T, Nagai R, Teramoto T, Atherosclerosis XIII. Proceedings of the 13th International Atherosclerosis Symposium.Elsevier. International Congress Series. 15 - 18. 2004

Ylä-Herttuala S. 2004. Viral vs. non-viral vectors for myocardial angiogenesis. NOGA LETTER 3: 11-12. 2004

Rissanen TT, Rutanen J, Ylä-Herttuala S. 2004. Gene transfer for therapeutic vascular growth in myocardial and peripheral ischemia ADVANCES IN GENETICS 52: 117-164. 2004

Aburawi E, Liuba P, Pesonen E, Ylä-Herttuala S, Sjöblad S. 2004. Acute respiratory viral infections aggravate arterial endothelial dysfunction in children with type 1 diabetes DIABETES CARE 27: 2733-2735. 2004

Petrova TV, Karpanen T, Norrmén C, Mellor R, Tamakoshi T, Finegold D, Ferrell R, Kerjaschki D, Mortimer P, Ylä-Herttuala S, Miura N, Alitalo K. 2004. Defective valves and abnormal mural cell recruitment underline lymphatic vascular failure in lymphedema distichiasis. NATURE MEDICINE 10: 974-981. 2004

Immonen A, Vapalahti M, Tyynelä K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N, Ylä-Herttuala S. 2004. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled stydy. MOLECULAR THERAPY 10 5: 967-972. 2004

Mähönen AJ, Airenne KJ, Lind MM, Lesch HP, Ylä-Herttuala S. 2004. Optimized self-excising Cre-expression cassette for mammalian cells. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 320 2: 366-371. 2004

Airenne KJ, Mähönen AJ, Laitinen OH, Ylä-Herttuala S. 2004. Baculovirus-mediated gene transfer: An evolving new concept. In: Templeton NS (ed.) , Gene and Cell Therapy.Marcel Dekker. ss. 181-197. 2004

Banning A, Schnurr K, Böl G-F, Kupper D, Müller-Schmehl K, Viita H, Ylä-Herttuala S, Brigelius-Flohe R. 2004. Inhibition of basal and interleukin-1-induced VCAM-1 expression by phospholipid hydroperoxide glutathione peroxidase and 15-lipoxygenase in rabbit aortic smooth muscle cells. FREE RADICAL BIOLOGY & MEDICINE 36 2: 135-144. 2004

Gruchala M, Roy H, Bhardwaj S, Ylä-Herttuala S. 2004. Gene therapy for cardiovascular diseases. CURRENT PHARMACEUTICAL DESIGN 10: 407-423. 2004

Hytönen VP, Laitinen OH, Airenne TT, Kidron H, Meltola NJ, Porkka EJ, Hörhä J, Paldanius T, Määttä JAE, Nordlund HR, Johnson MS, Salminen TA, Airenne KJ, Ylä-Herttuala S, Kulomaa MS. 2004. Efficient production of active chicken avidin using a bacterial signal peptide in Escherichia coli. BIOCHEMICAL JOURNAL 384: 385-390. 2004

Gruchala M, Bhardwaj S, Pajusola K, Roy H, Rissanen TT, Kokina I, Kholová I, Markkanen JE, Rutanen J, Heikura T, Alitalo K, Büeler H, Ylä-Herttuala S. 2004. Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors. JOURNAL OF GENE MEDICINE 6 5: 545-554. 2004

Kankkonen HM, Turunen MP, Hiltunen MO, Lehtolainen P, Koponen J, Leppänen P, Turunen A-M, Ylä-Herttuala S. 2004. Feline immunodeficiency virus and retrovirus-mediated adventitial ex vivo gene transfer to rabbit carotid artery using autologous vasvular smooth muscle cells. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY 36 3: 333-341. 2004

Kankkonen HM, Vähäkangas E, Marr RA, Pakkanen T, Laurema A, Leppänen P, Jalkanen J, Verma IM, Ylä-Herttuala S. 2004. Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy. MOLECULAR THERAPY 9 4: 548-556. 2004

Khurana T, Zhuang Z, Bhardwaj S, Murakami M, De Muinck E, Yla-Herttuala S, Ferrara N, Martin JF, Zachary I, Simons M. 2004. Angiogenesis-dependent and independent phases of intimal hyperplasia. CIRCULATION 110: 2436-2443. 2004

Koskinen K, Vainio PJ, Smith DJ, Pihlavisto M, Ylä-Herttuala S, Jalkanen S, Salmi M. 2004. Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). BLOOD 103 9: 3388-3395. 2004

Laurema A, Vanamo K, Heikkilä AL, Riekkinen M, Heinonen S, Ylä-Herttuala S. 2004. Fetal membranes act as a barrier for adenoviruses: gene transfer into exocoelomic cavity of rat features does not affect cells in the fetus. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 190 1: 264-267. 2004

Leppänen O, Rutanen J, Hiltunen MO, Rissanen TT, Turunen MP, Sjöblom T, Brüggen J, Bäckström G, Carlsson M, Buchdunger E, Bergqvist D, Alitalo K, Heldin C-H, Östman A, Ylä-Herttuala S. 2004. Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. CIRCULATION 109: 1140-1146. 2004

Rutanen J, Leppänen P, Tuomisto TT, Rissanen TT, Hiltunen MO, Vajanto I, Niemi M, Häkkinen T, Karkola K, Stacker SA, Achen MG, Alitalo K, Ylä-Herttuala S. 2003. Vascular endothelial growth factor-D expression in human atherosclerotic lesions. CARDIOVASCULAR RESEARCH 59: 971-979. 2003

Niskanen L, Lindi V, Erkkilä A, Sivenius K, Luoma J, Ylä-Herttuala S, Laakso M, Uusitupa MIJ, Laakso M. 2003. Association of the PRO12ALA polymorphism of the PPAR-gamma2 gene with oxidized low-density lipoprotein and cardiolipin autoantibodies in nondiabetic and type 2 diabetic subjects. METABOLISM: CLINICAL AND EXPERIMENTAL 52 2: 213-217. 2003

Nykänen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Ylä-Herttuala S, Koskinen PK, Lemström KB. 2003. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. CIRCULATION 107: 1308-1314. 2003

Pels K, Deiner C, Coupland SE, Noutsias M, Sutter AP, Schultheiss H-P, Yla-Herttuala S, Schwimmbeck PL. 2003. Effect of adventitial VEGF165 gene transfer on vascular thickening after coronary artery balloon injury CARDIOVASCULAR RESEARCH 60: 664-672. 2003

Rissanen TT, Markkanen JE, Arve K, Rutanen J, Kettunen MI, Vajanto I, Jauhiainen S, Cashion L, Gruchala M, Närvänen O, Taipale P, Kauppinen RA, Rubanyi GM, Ylä-Herttuala S. 2003. Fibroblast growth factor-4 induces vascular permeability, angiogenesis, and arteriogenesis in a rabbit hind limb ischemia model. FASEB JOURNAL 17: 100-102. 2003

Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholová I, Kauppinen RA, Achen MG, Stacker SA, Alitalo K, Ylä-Herttuala S. 2003. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses CIRCULATION RESEARCH 92: 1098-1106. 2003

Liuba P, Persson J, Luoma J, Ylä-Herttuala S, Pesonen E. 2003. Acute infections in children are accompanied by oxidative modification of LDL and decrease of HDL cholesterol, and are followed by thickening of carotid intima-media. EUROPEAN HEART JOURNAL 24 6: 515-521. 2003

Rubanyi GM, Ylä-Herttuala S. 2003. Preface: Rubanyi GM, Ylä-Herttuala S, Human Gene Therapy: Current Opportunities and Future Trends.Springer. V-VII. 2003

Ylä-Herttuala S. 2003. Hero or villain?. GENE THERAPY 10: 193. 2003

Tarkka T, Sipola A, Jämsä T, Soini Y, Ylä-Herttuala S, Tuukkanen J, Hautala T. 2003. Adenoviral VEGF-A gene transfer induces angiogenesis and promotes bone formation in healing osseous tissues. JOURNAL OF GENE MEDICINE 5: 560-566. 2003

The Foundation of a Medical Revolution. Ylä-Herttuala S. 2003 2003

Tuomisto TT, Korkeela A, Rutanen J, Viita H, Bräsen JH, Riekkinen M, Rissanen TT, Karkola K, Kiraly Z, Kölble K, Ylä-Herttuala S. 2003. Gene expression in macrophage-rich inflammatory cell infiltrates in human atherosclerotic lesions as studied by laser microdissection and DNA array. ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY 23: 2235-2240. 2003

Tuomisto TT, Ylä-Herttuala S. 2003. Genes involved in atherosclerosis and plaque formation. In: Van Eyk JE, Dunn MJ (ed.) , Proteomic and Genomic Analysis of Cardiovascular Disease.Wiley. ss. 141-151. 2003

Turunen MP, Hiltunen MO, Ylä-Herttuala S. 2003. Cardiovascular gene therapy. In: Rolland A, Sullivan SM (ed.) Pharmaceutical Gene Delivery Systems. Ei jufo-kustantaja/not jufo publisher. s. 345-362. 2003

Ylä-Herttuala S, Alitalo K. 2003. Gene transfer as a tool to induce therapeutic vascular growth. NATURE MEDICINE 9 6: 694-701. 2003

Ylä-Herttuala S. 2003. Angiogenesis clinical trials: Rubanyi GM, Ylä-Herttuala S, Human Gene Therapy: Current Opportunities and Future Trends.Springer. 19-23. 2003

Ylä-Herttuala S. 2003. Novel targeting of biotinylated compounds to local tissues with avidin-lipoprotein receptor fusion protein. DISCOVERY MEDICINE 3 19: 47-48. 2003

Ylä-Herttuala S. 2003. Percutaneous transcoronary venous access for cellular cardiomyoplasty. LANCET 362: 1252. 2003

Liuba P, Pesonen E, Paakkari I, Batra S, Andersen L, Forslid A, Ylä-Herttuala S, Persson K, Wadström T, Wang X, Laurini R. 2003. Co-infection with Chalamydia pneumoniae and Helicobacter pylori results in vascular endothelial dysfunction and enhanced VCAM-1 expression in apoE-knockout mice. JOURNAL OF VASCULAR RESEARCH 40: 115-122. 2003

Jalkanen J, Leppänen Pia, Närvänen O, Graeves DR, Ylä-Herttuala S. 2003. Adenovirus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor (SR-AI) in LDL receptor knock-out mice. ATHEROSCLEROSIS 169: 95-103. 2003

Lehtolainen P, Wirth T, Taskinen AK, Lehenkari P, Leppänen O, Lappalainen M, Pulkkanen K, Marttila A, Marjomäki V, Airenne KJ, Horton M, Kulomaa MS, Ylä-Herttuala S. 2003. Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein. GENE THERAPY 10 25: 2090-2097. 2003

Hiltunen MO, Ruuskanen M, Huuskonen J, Mähönen AJ, Ahonen M, Rutanen J, Kosma V-M, Mahonen A, Kröger H, Ylä-Herttuala S. 2003. Adenovirus-mediated VEGF-A gene transfer induces bone formation in vivo. FASEB JOURNAL 17: 1147-1149. 2003

A New Class of Biological Agents. The Design, Development and Testing of Ad5FGF-4 to Treat Ischaemic Heart Disease. Ylä-Herttuala S. 2003 2003

Airenne KJ, Peltomaa E, Hytönen VP, Laitinen OH, Ylä-Herttuala S. 2003. Improved generation of recombinant baculovirus genomes in Escherichia coli. NUCLEIC ACIDS RESEARCH 31: e101. 2003

Allart B, Lehtolainen P, Yla-Herttuala S, Martin JF, Selwood DL. 2003. A stable bis-allyloxycarbonyl biotin aldehyde derivative for biotinylation via reductive alkylation: application to the synthesis of a biotinylated doxorubicin derivative. BIOCONJUGATE CHEMISTRY 14: 187-194. 2003

Bhardwaj S, Roy H, Gruchala M, Viita H, Kholova I, Kokina I, Achen MG, Stacker SA, Hedman M, Alitalo K, Ylä-Herttuala S. 2003. Angiogenic responses of vascular endothelial growth factors in periadventitial tissue HUMAN GENE THERAPY 14: 1451-1462. 2003

Bräsen JH, Häkkinen T, Malle E, Beisiegel U, Ylä-Herttuala S. 2003. Patterns of oxidized epitopes, but not NF-kappaB expression, change during atherogenesis in WHHL rabbits. ATHEROSCLEROSIS 166 1: 13-21. 2003

Griffin JL, Lehtimäki KK, Valonen PK, Gröhn OHJ, Kettunen MI, Ylä-Herttuala S, Pitkänen A, Nicholson JK, Kauppinen RA. 2003. Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. CANCER RESEARCH 63: 3195-3201. 2003

Gröhn OHJ, Valonen PK, Lehtimäki KK, Väisänen TH, Kettunen MI, Ylä-Herttuala S, Kauppinen RA, Garwood M. 2003. Novel magnetic resonance imaging contrasts for monitoring response to gene therapy in rat glioma. CANCER RESEARCH 63: 7571-7574. 2003

Hedman M, Hartikainen J, Syvänne M, Stjernvall J, Hedman A, Kivelä A, Vanninen E, Mussalo H, Kauppila E, Simula S, Närvänen O, Rantala A, Peuhkurinen K, Nieminen MS, Laakso M, Ylä-Herttuala S. 2003. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II [...]. CIRCULATION 107: 2677-2683. 2003

Lehtimäki KK, Valonen PK, Griffin JL, Väisänen TH, Gröhn OHJ, Kettunen MI, Vepsäläinen J, Ylä-Herttuala S, Nicholson J, Kauppinen RA. 2003. Metabolite changes in BT4C rat gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death as studied by 1H NMR spectroscopy in vivo, ex vivo, and in vitro*. JOURNAL OF BIOLOGICAL CHEMISTRY 278 46: 45915-45923. 2003

Hiltunen MO, Ylä-Herttuala S. 2003. DNA methylation, smooth muscle cells. and atherogenesis. ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY 23: 1750-1753. 2003

Kukkonen SP, Airenne KJ, Marjomäki V, Laitinen OH, Lehtolainen P, Kankaanpää P, Mähönen AJ, Räty JK, Nordlund HR, Oker-Blom C, Kulomaa MS, Ylä-Herttuala S. 2003. Baculovirus capsid display: a novel tool for transduction imaging. MOLECULAR THERAPY 8 5: 853-862. 2003

Laurema A, Heikkilä A, Keski-Nisula L, Heikura T, Lehtolainen P, Manninen H, Tuomisto TT, Heinonen S, Ylä-Herttuala S. 2003. Transfection of oocytes and other types of ovarian cells in rabbits after direct injection into uterine arteries of adenoviruses and plasmid/liposomes GENE THERAPY 10: 580-584. 2003

Lampela P, Huotari M, Harjula A, Oinonen L, Ustav M, Ylä-Herttuala S, Männistö PT, Raasmaja A. 2003. Production of functional recombinant tyrosine hydroxylase by the BPV-1 expression plasmids in the cell cultures. PLASMID 50: 230-235. 2003

Iivanainen E, Nelimarkka L, Elenius V, Heikkinen S-M, Junttila TT, Sihombing L, Sundvall M, Määttä JA, Laine VJO, Ylä-Herttuala S, Higashiyama S, Alitalo K, Elenius K. 2003. Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB JOURNAL 17: 1609-1621. 2003

Kossila M, Pihlajamäki J, Kärkkäinen P, Miettinen R, Kekäläinen P, Vauhkonen I, Ylä-Herttuala S, Laakso M, Laakso M. 2003. Promoter polymorphisms -359T/C and -303A/G of the catalytic subunit p110beta gene of human phosphatidylinositol 3-kinase are not associated with insulin secretion or insulin sensitivity in Finnish subjects. DIABETES CARE 26: 179-182. 2003

Kleinman NS, Patel NC, Allen KB, Simons M, Ylä-Herttuala S, Griffin E, Dzau VJ. 2003. Evolving revascularization approaches for myocardial ischemia. AMERICAN JOURNAL OF CARDIOLOGY. SUPPLEMENT 92 9: 9N-17N. 2003

Jalkanen J, Leppänen P, Pajusola K, Närvänen O, Mähönen A, Vähäkangas E, Greaves DR, Büeler H, Ylä-Herttuala S. 2003. Adeno-associated virus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor reduces atherosclerotic lesion formation in LDL receptor knockout mice. MOLECULAR THERAPY 8 6: 903-910. 2003

Koponen JK, Kankkonen H, Kannasto J, Wirth T, Hillen W, Bujard H, Ylä-Herttuala S. 2003. Doxycycline-regulated lentiviral vector system with a novel reverse transactivator rtTA2S-M2 shows a tight control of gene expression in vitro and in vivo. GENE THERAPY 10 6: 459-466. 2003

Rutanen J, Markkanen J, Ylä-Herttuala S. 2002. Gene therapy for restenosis. Current status. DRUGS 62: 1575-1585. 2002

Pajusola K, Gruchala M, Joch H, Lüscher TF, Ylä-Herttuala S, Büeler H. 2002. Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells JOURNAL OF VIROLOGY 76 22: 11530-11540. 2002

Petrova TV, Mäkinen T, Mäkelä TP, Saarela J, Virtanen I, Ferrell RE, Finegold DN, Kerjaschki D, Ylä-Herttuala S, Alitalo K. 2002. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO JOURNAL 21 17: 4593-4599. 2002

Pulkkanen KJ, Laukkanen JM, Fuxe J, Kettunen MI, Rehn M, Kannasto JM, Parkkinen JJ, Kauppinen RA, Pettersson RF, Yla-Herttuala S. 2002. The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice CANCER GENE THERAPY 9: 908-916. 2002

Rissanen TT, Vajanto I, Hiltunen MO, Rutanen J, Kettunen MI, Niemi M, Leppänen P, Turunen MP, Markkanen JE, Arve K, Alhava E, Kauppinen RA, Ylä-Herttuala S. 2002. Expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in ischemic skeletal muscle and its regeneration. AMERICAN JOURNAL OF PATHOLOGY 160 4: 1393-1403. 2002

Turunen MP, Hiltunen MO, Ylä-Herttuala S. 2002. Local cardiovascular gene therapy: Mahato RI, Wan Kim S, Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics.Taylor & Francis. 487-498. 2002

Saaristo A, Veikkola T, Enholm B, Hytönen M, Arola J, Pajusola K, Turunen P, Jeltsch M, Karkkainen MJ, Kerjaschki D, Bueler H, Ylä-Herttuala S, Alitalo K. 2002. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB JOURNAL 16: 1041-1049. 2002

Saaristo A, Veikkola T, Tammela T, Enholm B, Karkkainen MJ, Pajusola K, Bueler H, Ylä-Herttuala S, Alitalo K. 2002. Lymphangiogenic gene therapy with minimal blood vascular side effects. JOURNAL OF EXPERIMENTAL MEDICINE 196 6: 719-730. 2002

Turunen MP, Puhakka HL, Koponen JK, Hiltunen MO, Rutanen J, Leppänen O, Turunen A-M, Närvänen A, Newby AC, Baker AH, Ylä-Herttuala S. 2002. Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer. MOLECULAR THERAPY 6: 306-312. 2002

Mäkinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E, Ylä-Herttuala S. 2002. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: A randomized, placebo-controlled, double-blinded phase II study. MOLECULAR THERAPY 6 1: 127-133. 2002

Vajanto I, Rissanen TT, Rutanen J, Hiltunen MO, Tuomisto TT, Arve K, Närvänen O, Manninen H, Räsänen H, Hippeläinen M, Alhava E, Ylä-Herttuala S. 2002. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. JOURNAL OF GENE MEDICINE 4: 371-380. 2002

Ylä-Herttuala S. 2002. Therapeutic angiogenesis: How far from clinical practice?. EVERYDAY PROBLEMS IN CLINICAL CARDIOLOGY 12 3: 4-7. 2002

Niemi M, Häkkinen T, Karttunen TJ, Eskelinen S, Kervinen K, Savolainen MJ, Lehtola J, Mäkelä J, Ylä-Herttuala S, Kesäniemi YA. 2002. Apolipoprotein E and colon cancer. Expression in normal and malignant human intestine and effect on cultured human colonic adenocarcinoma cells. EUROPEAN JOURNAL OF INTERNAL MEDICINE 13: 37-43. 2002

Tyynelä K, Sandmair A-M, Turunen M, Vanninen R, Vainio P, Kauppinen R, Johansson R, Vapalahti M, Ylä-Herttuala S. 2002. Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model CANCER GENE THERAPY 9 11: 917-924. 2002

Lemström KB, Krebs R, Nykänen AI, Tikkanen JM, Sihvola RK, Aaltola EM, Häyry PJ, Wood J, Alitalo K, Ylä-Herttuala S, Koskinen PK. 2002. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. CIRCULATION 105: 2524-2530. 2002

Hiltunen MO, Turunen MP, Häkkinen TP, Rutanen J, Hedman M, Mäkinen K, Turunen A-M, Aalto-Setälä K, Ylä-Herttuala S. 2002. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. VASCULAR MEDICINE (LONDON) 7: 5-11. 2002

Lehtolainen P, Tyynelä K, Kannasto J, Airenne KJ, Ylä-Herttuala S. 2002. Baculoviruses exhibit restricted cell type specificity in rat brain: a comparison of baculovirus- and adenovirus-mediated intracerebral gene transfer in vivo GENE THERAPY 9: 1693-1699. 2002

Bräsen JH, Koenig K, Bach H, Kontush A, Heinle H, Witting PK, Ylä-Herttuala S, Stocker R, Beisiegel U. 2002. Comparison of the effects of alpha-tocopherol, ubiquinone-10 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits. ATHEROSCLEROSIS 163: 249-259. 2002

Hakumäki JM, Gröhn OHJ, Tyynelä K, Valonen P, Ylä-Herttuala S, Kauppinen RA. 2002. Early gene therapy - induced apoptotic response in BT4C gliomas by magnetic resonance relaxation contrast T1 in the rotating frame. CANCER GENE THERAPY 9: 338-345. 2002

He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. 2002. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling JOURNAL OF THE NATIONAL CANCER INSTITUTE 94 11: 819-825. 2002

Heikkilä A, Myllynen P, Keski-Nisula L, Heinonen S, Vähäkangas K, Ylä-Herttuala S. 2002. Gene transfer to human placenta ex vivo: A novel application of dual perfusion of human placental cotyledon. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 186: 1046-1051. 2002

Hiltunen MO, Tuomisto TT, Niemi M, Bräsen JH, Rissanen TT, Törönen P, Vajanto I, Ylä-Herttuala S. 2002. Changes in gene expression in atherosclerotic plaques analyzed using DNA array. ATHEROSCLEROSIS 165: 23-32. 2002

Rutanen J, Puhakka H, Ylä-Herttuala S. 2002. Post-intervention vessel remodeling. GENE THERAPY 9: 1487-1491. 2002

Koponen JK, Turunen A-M, Ylä-Herttuala S. 2002. Escherichia coli DNA contamination in AmpliTag Gold polymerase interferes with TagMan analysis of IacZ. MOLECULAR THERAPY 5 3: 220-222. 2002

Lehtolainen P, Taskinen A, Laukkanen J, Airenne KJ, Heino S, Lappalainen M, Ojala K, Marjomäki V, Martin JF, Kulomaa MS, Ylä-Herttuala S. 2002. Cloning and characterization of Scavidin, a fusion protein for the targeted delivery of biotinylated molecules. JOURNAL OF BIOLOGICAL CHEMISTRY 277 10: 8545-8550. 2002

Kossila M, Jauhiainen S, Laukkanen MO, Lehtolainen P, Jääskeläinen M, Turunen P, Loimas S, Wahlfors J, Ylä-Herttuala S. 2002. Improvement in adenoviral gene transfer efficiency after preincubation at +37oC in vitro and in vivo. MOLECULAR THERAPY 5 1: 87-93. 2002

Lampela P, Räisänen J, Männistö PT, Ylä-Herttuala S, Raasmaja A. 2002. The use of low-molecular-weight PEIs as gene carriers in the monkey fibroblastoma and rabbit smooth muscle cell cultures. JOURNAL OF GENE MEDICINE 4 2: 205-214. 2002

Laukkanen J, Ylä-Herttuala S. 2002. Cloning and characterization of soluble decoy receptors: Sen CK, Packer L, Redox Cell Biology and Genetics. Part B.Elsevier. Methods in Enzymology. 337-345. 2002

Laukkanen J, Ylä-Herttuala S. 2002. Genes involved in atherosclerosis NEPHRON. EXPERIMENTAL NEPHROLOGY 10: 150-163. 2002

Laukkanen MO, Kivelä A, Rissanen T, Rutanen J, Karkkainen MK, Leppanen O, Bräsen JH, Yla-Herttuala S. 2002. Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta. CIRCULATION 106: 1999-2003. 2002

Ylä-Herttuala S. 2001. Gene therapy for coronary heart disease. JOURNAL OF INTERNAL MEDICINE 250: 367-368. 2001

Ylä-Herttuala S. 2001. Geeniterapia SUOMEN PROVIISORILEHTI 1: 10. 2001

Sentman M-L, Brännström T, Westerlund S, Laukkanen MO, Ylä-Herttuala S, Basu S, Marklund SL. 2001. Extracellular superoxide dismutase deficiency and atherosclerosis in mice. ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY 21: 1477-1482. 2001

Rutanen J, Rissanen TT, Kivelä A, Vajanto I, Ylä-Herttuala S. 2001. Clinical applications of vascular gene therapy. CURRENT CARDIOLOGY REPORTS 3: 29-36. 2001

Rissanen TT, Vajanto I, Ylä-Herttuala S. 2001. Gene therapy for therapeutic angiogenesis in critically inschaemic lower limb - on the way to the clinic. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 31: 651-666. 2001

Pulkkanen KJ, Parkkinen JJ, Laukkanen JM, Kettunen MI, Tyynela K, Kauppinen RA, Ala-Opas MY, Yla-Herttuala S. 2001. HSV-tk gene therapy for human renal cell carcinoma in nude mice. CANCER GENE THERAPY 8: 529-536. 2001

Närvänen O, Erkkilä A, Ylä-Herttuala S. 2001. Evaluation and characterization of EIA measuring autoantibodies against oxidized LDL FREE RADICAL BIOLOGY & MEDICINE 31 6: 769-777. 2001

Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S-I, Ylä-Herttuala S, Alitalo K. 2001. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 NATURE MEDICINE 7 2: 199-205. 2001

Leppänen PM, Koponen J, Turunen MP, Pakkanen T, Ylä-Herttuala S. 2001. Optimized in situ PCR method for the detection of gene transfer vector in histological sections. JOURNAL OF GENE MEDICINE 3: 173-178. 2001

Närvänen O, Luoma J, Ylä-Herttuala S. 2001. Technical and clinical aspects about autoantibody assays for oxidized low density lipoprotein: Shoenfeld Y, Harats D, Wick G, Atherosclerosis and Autoimmunity. Section V. Anti-Endothelial Cell Antibodies and Atherosclerosis.Elsevier. 173-179. 2001

Laukkanen MO, Leppanen P, Turunen P, Tuomisto T, Naarala J, Yla-Herttuala S. 2001. EC-SOD gene therapy reduces paracetamol-induced liver damage in mice. JOURNAL OF GENE MEDICINE 3: 321-325. 2001

Greaves DR, Häkkinen T, Lucas AD, Liddiard K, Jones E, Quinn CM, Senaratne J, Green FR, Tyson K, Boyle J, Shanahan C, Weissberg PL, Gordon S, Ylä-Hertualla S. 2001. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY 21: 923-929. 2001

Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Ylä-Herttuala S, Jäättelä M, Alitalo K. 2001. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth CANCER RESEARCH 61: 1786-1790. 2001

Bräsen JH, Kivelä A, Röser K, Rissanen TT, Niemi M, Luft FC, Donath K, Ylä-Herttuala S. 2001. Angiogenesis, vascular endothelial growth factor and platelet-derived growth factor-BB expression, iron deposition, and oxidation-specific epitopes in stented human coronary arteries ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY 21: 1720-1726. 2001

Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, Jackson DG, Yla-Herttuala S, Alitalo K. 2001. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. CIRCULATION RESEARCH 88: 623-629. 2001

Laukkanen MO, Leppänen P, Turunen P, Porkkala-Sarataho E, Salonen JT, Ylä-Herttuala S. 2001. Gene transfer of extracellular superoxide dismutase to atherosclerotic mice. ANTIOXIDANTS AND REDOX SIGNALING 3 3: 397-402. 2001

Heikkilä A, Hiltunen MO, Turunen MP, Keski-Nisula L, Turunen A-M, Räsänen H, Rissanen TT, Kosma V-M, Manninen H, Heinonen S, Ylä-Herttuala S. 2001. Angiographically guided utero-placental gene transfer in rabbits with adenoviruses, plasmid/liposomes and plasmid/polyethyleneimine complexes. GENE THERAPY 8: 784-788. 2001

Hiltunen TP, Gough PJ, Greaves DR, Gordon S, Ylä-Herttuala S. 2001. Rabbit atherosclerotic lesions express scavenger receptor AIII mRNA, a naturally occurring splice variant that encodes a non-functional, dominant negative form of the macrophage scavenger receptor. ATHEROSCLEROSIS 154: 415-419. 2001

Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, Bueler H, Eichmann A, Kauppinen R, Kettunen MI, Ylä-Herttuala S, Finegold DN, Ferrell RE, Alitalo K. 2001. A model for gene therapy of human hereditary lymphedema. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 98 22: 12677-12682. 2001

Heydeck D, Upston JM, Viita H, Ylä-Herttuala S, Stocker R. 2001. Oxidation of LDL by rabbit and human 15-lipoxygenase: prevalence of nonenzymatic reactions. JOURNAL OF LIPID RESEARCH 42: 1082-1088. 2001

Sandmair A-M, Vapalahti M, Ylä-Herttuala S. 2000. Adenovirus-mediated herpes simplex thymidine kinase gene therapy for brain tumors: Habib NA, Cancer Gene Therapy. Past Achievements and Future Challenges.Kluwer. Advances in Experimental Medicine and Biology. 163-170. 2000

Pakkanen TM, Laitinen M, Hippeläinen M, Hiltunen MO, Alhava E, Ylä-Herttuala S. 2000. Periadventitial lacZ gene transfer to pig carotid arteries using a biodegradable collagen collar or a wrap of collagen sheet with adenoviruses and plasmid-liposome complexes. JOURNAL OF GENE MEDICINE 2: 52-60. 2000

Pulkkanen KJ, Laukkanen MO, Naarala J, Yla-Herttuala S. 2000. False-positive apoptosis signal in mouse kidney and liver detected with TUNEL assay APOPTOSIS 5 4: 329-333. 2000

Pulkkanen KJ, Parkkinen JJ, Kettunen MI, Kauppinen RA, Lappalainen M, Ala-Opas MY, Ylä-Herttuala S. 2000. Characterization of a new animal model for human renal cell carcinoma. IN VIVO (ATHENS) 14: 393-400. 2000

Sandmair A-M, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, Tyynelä K, Turunen M, Vanninen R, Lehtolainen P, Paljärvi L, Johansson R, Vapalahti M, Ylä-Herttuala S. 2000. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. HUMAN GENE THERAPY 11: 2197-2205. 2000

Sandmair A-M, Turunen M, Tyynelä K, Loimas S, Vainio P, Vanninen R, Vapalahti M, Bjerkvig R, Jänne J, Ylä-Herttuala S. 2000. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions CANCER GENE THERAPY 7 3: 413-421. 2000

Viita H, Ylä-Herttuala S. 2000. Effects of lipoxygenases on gene expression in mammalian cells. In: Sen CK, Sies H, Baeuerle PA (ed.) , Antioxidant and Redox Regulation of Genes.Academic Press. ss. 339-358. 2000

Sandmair A-M, Vapalahti M, Ylä-Herttuala S. 2000. Adenoviruses as gene delivery vectors: Habib NA, Cancer Gene Therapy. Past Achievements and Future Challenges.Kluwer. Advances in Experimental Medicine and Biology. 423-429. 2000

Viluksela M, Ylä-Hertt

SEPPO YLä-HERTTUALA

Contact info

Organization

Email

Phone

Publications